2024 | 2023 | 2022 | 2021 | 2020 |2019 | 2018 | 2017 |2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993

1. 2024

   1. 1. New! Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamori J, Kawamura M, Ogita M, Yamamoto Y, Iwata H, Saji S. The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition. Breast Cancer. In press.
      2. New! Ueta A, Yamada A, Yoshioka M, Kanai M, Muto M, Okita N. Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring TFG-MET fusion. International Cancer Conference Journal. 2024;1.5.
      3. New! Kishi N, Yoneyama M, Inoo H, Inoue M, Iramina H, Nakakura A, Ono T, Hirashima H, Adachi T, Matsushita N, Sasaki M, Fujimoto T, Nakamura M, Matsuo Y, Mizowaki T. Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study). Radiation Oncology. 2024;19:32.
      4. Kishi N, Matsuo Y. Postoperative radiotherapy for thymic epithelial tumors: a narrative review. Mediastinum. 2024.
      5. Ono T, Hirashima H, Adachi T, Iramina H, Fujimoto T, Uto M, Nakamura M, Mizowaki T. Influence of dose calculation algorithms on the helical diode array using volumetric-modulated arc therapy for small targets. J Appl Clin Med Phys. 2024;314307.

      2023

      1. Adachi T, Nakamura M, Iramina H, Matsumoto K, Ishihara Y, Tachibana H, Kurokawa S, Cho S, Tanaka K, Fukumoto K, Nishiyama T, Kito S, Mizowaki T. Identification of reproducible radiomic features from on-board volumetric images: A multi-institutional phantom study. Med Phys. 2023; 50: 5585-5596.
      2. Akimoto T, Aoyama H, Chua MLK, Jayamanne D, Mizowaki T, Morris L, Onishi H, Song SY, Zeidan YH, Sharma RA. Challenges and Opportunities With the Use of Hypofractionated Radiation Therapy in Cancer Care: Regional Perspectives From South Korea, Japan, Singapore, and Australia. Adv Radiat Oncol. 2023; 8: 101291.
      3. Hirashima H, Nakamura M, Imanishi K, Nakao M, Mizowaki T. Evaluation of generalization ability for deep learning-based auto-segmentation accuracy in limited field of view CBCT of male pelvic region. J Appl Clin Med Phys. 2023; e13912.
      4. Hirashima H, Nakamura M, Nakamura K, Matsuo Y, Mizowaki T. Dosimetric verification of four dose calculation algorithms for spine stereotactic body radiotherapy. J Radiat Res. 2023; 65(1): 109-118.
      5. Hiraoka S, Yoshimura M, Nakajima A, Nakashima R, Mizowaki T. Long-term outcomes of stimulated salivary flow and xerostomia after definitive intensity-modulated radiation therapy for patients with head and neck cancerdagger. J Radiat Res. 2023; 65(1): 71-77.
      6. Iizuka Y, Hiraoka M, Kokubo M, Sakamoto T, Karasawa K, Murofushi K, Nakamura M, Matsuo Y, Morita S, Inokuchi H, Mizowaki T. Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. Clin Transl Radiat Oncol. 2023; 39: 100591.
      7. Iramina H, Nakamura M, Nakamura K, Fujimoto T, Mizowaki T. Quantification of six-degree-of-freedom motion during beam delivery in spine stereotactic body radiotherapy using intra-irradiation cone-beam computed tomography imaging technique. Phys Med. 2023; 110: 102605.
      8. Iwai T, Imagumbai T, Okabayashi S, Ashida R, Mitsuyoshi T, Tai Y, Matsumoto T, Yamashita D, Nagono T, Kokubo M.  Perianal Bowen’s disease treated with radiotherapy preserving anal function with a unique skin reaction considered as ‘tumoritis’. International Cancer Conference Journal. 2023; 12: 41-45.
      9. Iwai T, Imagumbai T, Hiraoka S, Kishi T, Okabayashi S, Ashida R, Mitsuyoshi T, Matsuo Y, Ishigaki T, Mizowaki T, Kokubo M. Clinical outcomes of scalp or face angiosarcoma treatment with intensity-modulated radiotherapy: a multicenter study. J Radiat Res. 2023; 65(1): 78-86.
      10. Kawamoto T, Yasuda K, Ito Y, Zenda S, Sakanaka K, Shikama N, Nakamura N, Mizowaki T. Adjuvant treatments for locally advanced differentiated thyroid cancer: a nationwide survey in Japan. Endocr J. 2023; 70(10): 999-1003.
      11. Kawata K, Hirashima H, Tsuruta Y, Sasaki M, Matsushita N, Fujimoto T, Nakamura M, Nakata M. Applicability evaluation of the TRS-483 protocol for the determination of small-field output factors using different multi-leaf collimator and field-shaping types. Phys Med. 2023; 113: 102664.
      12. Kawata K, Ono T, Hirashima H, Tsuruta Y, Fujimoto T, Nakamura M, Nakata M. Effect of angular dependence for small-field dosimetry using seven different detectors. Med Phys. 2023; 50:1274-1289.
      13. Kido T, Ono T, Nakamura M, Ishihara Y, Itoh H, Matsugi K, Yoshimoto A, Kishigami Y, Mizowaki T. Development and multi-institutional evaluation of a new phantom for verifying beam-positioning errors at off-isocenter positions. Phys Med. 2023; 112: 102645.
      14. Kikuchi M, Nakagawa T, Kitada Y, Matsunaga M, Tanji M, Hiraoka S, Nakashima R, Nakajima A, Yoshimura M, Omori K. Long-term survival outcomes and recurrence patterns of olfactory neuroblastoma: A 13-year experience at a single institution. Auris Nasus Larynx. 2023; 50(4): 550-557.
      15. Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T, Kyoto Radiation Oncology Study Group. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res. 2023; 64: 142-153. 
      16. Kishimoto Y, Kawai Y, Fujimura S, Komurasaki A, Sakanaka K, Tsunoda S, Mizowaki T, Obama K, Muto M, Omori K. Outcome of selective neck dissection for cervical lymph node recurrence or residual lymph node metastasis of oesophageal cancer. Clin Otolaryngol. 2023; 49(1): 152-157.
      17. Kito S, Mukumoto N, Nakamura M, Tanabe H, Karasawa K, Kokubo M, Sakamoto T, Iizuka Y, Yoshimura M, Matsuo Y, Hiraoka M, Mizowaki T. Population-based asymmetric margins for moving targets in real-time tumor tracking. Med Phys. 2023; 51(3): 1561-1570.
      18. Kodaira T, Kagami Y, Machida R, Shikama N, Sekino Y, Ito Y, Ishikura S, Saito Y, Matsumoto Y, Konishi K, Murakami N, Akimoto T, Fukushima Y, Toshiyasu T, Katano A, Nagata Y, Ogawa H, Uno T, Hamamoto Y, Nishimura Y, Mizowaki T. Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3). Int J Radiat Oncol Biol Phys. 2023; 5: 1118-1124.
      19. Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A, Yoshimura M, Mizowaki T, Uza N, Fukuda A, Matsumoto S, Kanai M, Isoda H, Kawaguchi Y, Uemoto S, Hatano E. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study. Cancer Med. 2023; 18: 18611-18621.
      20. Matsuo Y. Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. Curr Oncol. 2023; 18: 2493-2500.
      21. Matsuo Y, Kishi N, Ueki K, Yoneyama M. Lung: toxicities. In: Nagata Y, ed. Stereotactic Body Radiation Therapy, Second Edition. Springer Japan. 2023.
      22. Mitsuyoshi T, Ono Y, Ashida R, Yamashita M, Tanabe H, Takebe S, Tokiwa M, Suzuki E, Imagumbai T, Yoshimura M, Yamauchi C, Mizowaki T, Kokubo M. Multi-institutional phase II study of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for breast cancer in Japan: Kyoto Radiation Oncology Study Group (UPBEAT study). Jpn J Clin Oncol. 2023; 53: 174-178.
      23. Nakamura K, Norihisa Y, Ikeda I, Inokuchi H, Aizawa R, Kamoto T, Kamba T, Inoue T, Yamasaki T, Akamatsu S, Kobayashi T, Ogawa O, Mizowaki T. Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis. Cancer Med. 2023; 12: 7859-7867.
      24. Ogawa A, Nakamura M, Iramina H, Yoshimura M, Mizowaki T. Potential utility of cone-beam CT-guided adaptive radiotherapy under end-exhalation breath-hold conditions for pancreatic cancer. J Appl Clin Med Phys. 2023; 24: e13827.
      25. Ogawa A, Yoshimura M, Nakamura M, Adachi T, Iwai T, Ashida R, Mizowaki T. Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced pancreatic ductal adenocarcinoma. Radiat Oncol. 2023; 18: 103.
      26. Okamoto H, Murakami N, Isohashi F, Kasamatsu T, Hasumi Y, Kobayashi H, Ishikawa M, Nakamura M, Nishio T, Igaki H, Ishikura S, Yaegashi N, Mizowaki T, Nishimura Y, Toita T. Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402). 2023; Radiother Oncol. 2023; 183: 109630.
      27. Ono T, Kawata K, Nakamura M, Uto M, Mizowaki T. Small-feld dosimetry with detector-specifc output correction factor for single-isocenter stereotactic radiotherapy of single and multiple brain metastases. Radiol Phys Technol. 2023; 16: 10-19.
      28. Ono T, Kido T, Nakamura M, Iramina H, Kakino R, T Mizowaki. Automatic measurement of beam-positioning accuracy at off-isocenter positions. J Appl Clin Med Phys. 2023; 24: e13844.
      29. Sakurai Y, Ambo S, Nakamura M, Iramina H, Iizuka Y, Mitsuyoshi T, Matsuo Y, Mizowaki T. Development of a prediction model for target positioning by using diaphragm waveforms extracted from CBCT projection images. J Appl Clin Med Phys. 2023: 24: e14112.
      30. Sano T, Aizawa R, Ito K, Nakamura K, Ogata T, Takeda M, Hamada A, Matsuoka T, Kono J, Kita Y, Masui K, Goto T, Sawada A, Akamatsu S, Ogawa O, Mizowaki T, Kobayashi T. Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma. Anticancer Res. 2023; 43: 2119-2126.
      31. Sano T, Saito R, Aizawa R, Watanabe T, Murakami K, Kita Y, Masui K, Goto T, Mizowaki T, Kobayashi T. Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma. Int J Clin Oncol. 2023; 12: 157-84.
      32. Sasaki K, Nomura M, Kato K, Sakanaka K, Ito Y, Kadota T, Machida R, Kataoka T, Minashi K, Tsubosa Y, Kajiwara T, Fukuda H, Takeuchi H, Mizowaki T, Nishimura Y, Kitagawa Y. A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904). Jpn J Clin Oncol. 2023; 54(1): 103-107.
      33. Tamari K, Nagata Y, Mizowaki T, Kodaira T, Onishi H, Ogawa K, Shioyama Y, Shigematsu N, Uno T. The impact of the COVID-19 pandemic on radiotherapy in Japan: nationwide surveys from May 2020 through June 2021. J Radiat Res. 2023; 64: 126-132.
      34. Tamari K, Kishigami M, Nagata Y, Mizowaki T, Kodaira T, Onishi H, Ogawa K, Shioyama Y, Shigematsu N, Uno T. The impact of the COVID-19 pandemic on radiotherapy delivery in Japan: An observational study based on the national database. Cancer Med. 2023; 12: 21032-40.
      35. Torizuka D. Uto M, Umeda K, Kamitori T, Iwai A, Saida S, Kato I, Mineharu Y, Arakawa Y, Takita J, Mizowaki T. A scalp dose threshold for preventing permanent alopecia in scalp-avoidance whole-brain irradiation with volumetric-modulated arc radiotherapy (SAWB-VMAT) for pediatric patients with medulloblastomas. Int J Radiat Oncol Biol Phys. 2023; 116: 889-893.
      36. Torizuka D. Uto M, Mizowaki T. Dosimetric impact of adding non-coplanar arcs for scalp-avoidance whole-brain irradiation with volumetric-modulated arc radiotherapy on scalp dose reduction in pediatric patients with medulloblastomas. J Appl Clin Med Phys. 2024;25(2):e14189.
      37. Umeda K, Sakamoto A, Noguchi T, Uchihara Y, Kobushi H, Akazawa R, Ogata H, Saida S, Kato I, Hiramatsu H, Uto M, Mizowaki T, Haga H, Date H, Okamoto T, Watanabe K, Adachi S, Toguchida J, Matsuda S, Takita J. Clinical Outcomes of Patients with Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience. J Pediatr Hematol Oncol. 2023; 45: e356-e362.
      38. Watanabe T, Sato G.E, Yoshimura M, Suzuki M, Mizowaki T. The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. Int J Clin Oncol. 2023; 28: 201-208.
      39. Yokota T, Zenda S, Kodaira T, Kiyota N, Fujimoto Y, Wasano K, Takahashi R, Mizowaki T, Homma A, Sasaki K, Machida R, Sekino Y, Fukuda H; Japan Clinical Oncology Group Radiation Therapy Study Group; Japan Clinical Oncology Group Head and Neck Cancer Study Group. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE). BMC Cancer. 2023; 23: 1068.
      40. Zhou D, Nakamura M, Mukumoto N, Matsuo Y, Mizowaki T. Feasibility Study of Deep Learning-based Markerless Real-time Lung Tumor Tracking with Orthogonal X-ray Projection Images.  J Appl Clin Med Phys. 2023; 24: e13894.
      41. Zhou D, Nakamura M, Sawada Y, Ono T, Hirashima H, Iramina H, Adachi T, Fujimoto T, Mizowaki T. Development of independent dose verification plugin using Eclipse scripting API for brachytherapy. J. Radiat. Res. 2023; 64: 180-185.

      2022

      1. Aizawa R, Tsuzuki T, Haga H, Nakamura K, Ogata T, Inoue T, Kobayashi T, Akamatsu S, Goto T, Ogawa O, Mizowaki T. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Sci. 2022; 113: 2425-2433.
      2. Arakawa Y, Mineharu Y, Uto M, Mizowaki T. Optimal managements of elderly patients with glioblastoma. Jpn J Clin Oncol. 2022; 52: 825-834.
      3. Asada H, Takahashi Y, Ono Y, Kishi N, Matsuo Y, Mizowaki T, Nakayama T. Emotional Experiences of Skin Markings Among Patients Undergoing Radiotherapy and Related Factors: A Questionnaire-Based Cross-Sectional Study. Patient Prefer Adherence. 2022; 16: 1359-1369.
      4. Adachi T, Nagasawa R, Nakamura M, Kakino R, Mizowaki T. Vulnerabilities of radiomic features to respiratory motion on four-dimensional computed tomography-based average intensity projection images: A phantom study. J Appl Clin Med Phys. 2022; 23: e13498.
      5. Adachi T, Nakamura M, Kakino R, Hirashima H, Iramina H, Tsuruta Y, Ono T, Mukumoto N, Miyabe Y, Matsuo Y, Mizowaki T. Dosiomic feature comparison between dose-calculation algorithms used for lung stereotactic body radiation therapy. Radiol Phys Technol. 2022; 15: 63-71.
      6. Inoo H, Sakanaka K, Fujii K, Ishida Y, Mizowaki T. Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer. J Radiat Res. 2022; 63: 646-656. 
      7. Inoue R, Sawamura M, Yoshimura M, Takahashi R. Dropped head syndrome due to chemoradiotherapy for nasal lymphoma, characterised by short tau inversion recovery high signal intensity in the cervical paraspinal muscles. BMJ Case Rep. 2022; 15: e252446.
      8. Kishi N, Matsuo Y, Menju T, Hamaji M, Nakakura A, Hanazawa H, Takehana K, Date H,  Mizowaki T. Propensity score-based analysis of stereotactic body radiotherapy, lobectomy and sublobar resection for stage I non-small cell lung cancer. J Radiat Res. 2022; 63: 758-771. 
      9. Kishi N, Matsuo Y, Yoneyama M, Ueki k, Mizowaki T. Symptomatic radiation pneumonitis after stereotactic body radiotherapy for multiple pulmonary oligometastases or synchronous primary lung cancer. Advances in Radiation Oncology. 2022; 7: 100911. 
      10. Kishi N, Matsuo Y, Hanazawa H, Iizuka Y, Mizowaki T. Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancer. Plos One. 2022; 17: e0269463.
      11. Kishi N, Matsuo Y. Role of radiotherapy in multidisciplinary treatment and considerations for its use. 最新臨床肺癌学. 2022; 80: p466-471.
      12. Masui T, Nagai K, Anazawa T, Sato A, Uchida Y, Nakano K, Yogo A, Kaneda A, Nakamura N, Yoshimura M, Mizowaki T, Uza N, Fukuda A, Matsumoto S, Kanai M, Isoda H, Mizumoto M, Seo S, Hata K, Taura K, Kawaguchi Y, Takaori K, Uemoto S, Hatano E. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution. BMC Cancer. 2022; 22: 1-11.
      13. Matsuo Y, Hiraoka M, Karasawa K, Kokubo M, Sakamoto T, Mukumoto N, Nakamura M, Morita S, and Mizowaki T. Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. Radiother Oncol. 2022; 172: 18-22.
      14. Matsuo Y, Hanazawa H, Kishi N, Ueki K, Mizowaki M. Radiation Therapy for Intrathoracic Recurrence of Lung Cancer. In: Jeremić, B. ed. Advances in Radiation Oncology in Lung Cancer, Third Edition. Springer Japan. 2022.
      15. Mizowaki T. SABR for primary renal cell carcinoma: single-fraction or multiple-fraction? Lancet Oncol. 2022; 23: 1476-1477.
      16. Murakami T, Aizawa R, Matsuo Y, Hanazawa H, Taura K, Fukuda A, Uza N, Shiokawa M, Kanai M, Hatano E, Seno H, Muto M, Mizowaki T. Efficacy and Safety of External-beam Radiation Therapy for Unresectable Primary or Local Recurrent Cholangiocarcinoma. Cancer Diagn Progn. 2022; 2: 634-640.
      17. Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T, Japanese Urological Oncology, Group. Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy. Int J Urol. 2022; 29: 1147-1154.
      18. Ono T, Nakamura M, Ono Y, Nakamura K, Mizowaki T. Development of a plan complexity mitigation algorithm based on gamma passing rate predictions for volumetric-modulated arc therapy. Med Phys. 2022; 49: 1793-1802. 
      19. Otani T, Saga T, Ishimori T, Kidera E, Shimizu Y, Aizawa R, Nakamura K, Goto T, Akamatsu S, Mizowaki T, Nakamoto Y. Detection efficacy of PET/CT with (18)F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med. 2022; 36: 302-309.
      20. Sakanaka K, Fujii K, Ishida Y, Mukumoto N, Hida K, Inoo H, Sakai Y, Mizowaki T. Preoperative chemoradiotherapy for locally advanced low rectal cancer using intensity-modulated radiotherapy to spare the intestines: a single-institutional pilot trial. J Radiat Res. 2022; 20: 88-97.
      21. Takehana K, Sakamoto R, Fujimoto K, Matsuo Y, Nakajima N, Yoshizawa A, Menju T, Nakamura M, Yamada R, Mizowaki T, Nakamoto Y. Peritumoral radiomics features on preoperative thin-slice CT images can predict the spread through air spaces of lung adenocarcinoma. Sci Rep. 2022; 12: 10323
      22. Takeno S, Tanaka H, Ono K, Mizowaki T, Suzuki M. Analysis of boron neutron capture reaction sensitivity using Monte Carlo simulation and proposal of a new dosimetry index in boron neutron capture therapy. J Radiat Res. 2022; 63: 780-791.

      23. Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 2022; 114: 454-462.

      24. Tateishi Y, Sakanaka K, Hirashima H, Mukumoto N, Inoo H, Fujii K, Ono T, Nakamura M, Nakata M, Kawasaki K, Tani H, Mandai Masaki, Mizowaki T. A case of a pregnant woman with locally advanced cervical esophageal cancer treated with definitive chemoradiotherapy. International Cancer Conference Journal. 2022; 11: 292-297.
      25. Terada N, Aizawa R, Nihei K, Shiota M, Kojima T, Kimura T, Inoue T, Kitamura H, Sugimoto M, Nishiyama H, Mizowaki T, Kamoto T. Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer. Jpn J Clin Oncol. 2022; 52: 633-641.
      26. Tsuruta Y, Nakamura M, Nakata M, Hirashima H, Zhou D, Uto M, Takehana K, Fujimoto T, Mizowaki T. Evaluation of correlation between intrafractional residual setup errors and accumulation of delivered dose distributions in single isocenter volumetric modulated arc therapy for multiple brain metastases. Phys Med. 2022; 98: 45-52.
      27. Ueki K, Matsuo Y, Takeda A, Morita S, Taguri M, Kishi N, Hanazawa H, Tsurugai Y, Mizowaki T. Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model. Int J Radiat Oncol Biol Phys. 2022; 112: 1135-1143. 
      28. Ueki K, Matsuo Y, Kishi N, Yoneyama M, Yoshida H, Sakamori Y, Ozasa H, Hirai T, Mizowaki T. Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer. J Radiat Res. 2022; 63: 636-645.
      29. Umeda K, Taura K, Kato I, Saida S, Hiramatsu H, Shimizu H, Nakamoto Y, Uto M, Mizowaki T, Sakamoto A, Adachi S, Okamoto T, Takita J. Intensive Multimodal Therapy Combined With Long-term Temozolomide and Etoposide Treatment for Recurrent Osteosarcoma to the Liver and Stomach. J Pediatr Hematol Oncol. 2022; 44: 175-177.
      30. Uto M, Torizuka D, Mizowaki T. Single isocenter stereotactic irradiation for multiple brain metastases: current situation and prospects. Jpn J Radiol. 2022; 40: 987-994.
      31. Watanabe M, Kawai-Miyake K, Fushimi Y, Ishimori T, Nakajima A, Yoshimura M, Kikuchi M, Ohno K, Nakamoto Y. Application of a Flexible PET Scanner Combined with 3 T MRI Using Non-local Means Reconstruction: Qualitative and Quantitative Comparison with Whole-Body PET/CT. Mol Imaging Biol. 2022; 24: 167-176.
      32. Zhou D, Nakamura M, Mukumoto N, Yoshimura M, Mizowaki T. Development of a Deep Learning-based Patient-specific Target Contour Prediction Model for Markerless Tumor Positioning. Med Phys. 2022; 49: 1382-1390. 
      33. Zhou D, Nakamura M, Mukumoto N, Tanabe H, Iizuka Y, Yoshimura M, Kokubo M, Matsuo Y, Mizowaki T. Development of AI-driven prediction models to realize real-time tumor tracking during radiotherapy. Radiat Oncol. 2022; 17: 1-14. 
      34. Wu S, Nakao M, Imanishi K, Nakamura M, Mizowaki T, Matsuda T. Computed Tomography slice interpolation in the longitudinal direction based on deep learning techniques: To reduce slice thickness or slice increment without dose increase. PLoS One. 2022; 17: e0279005.

   2021

   1. Abdelghaffar A, Kishi N, Ashida R, Matsuo Y, Hirashima H, Mukumoto N, Yoshimura M, Nakamura M, Mohamed AES, Ali EM, Gaber MS, Mizowaki T. Dosimetric comparison between dynamic wave arc and co-planar volumetric modulated radiotherapy for locally advanced pancreatic cancer. Iran J Med Phys. 2022; 19: 1-8. 
   2. Adachi T, Nakamura M, Shintani T, Mitsuyoshi T, Kakino R, Ogata T, Ono T, Tanabe H, Kokubo M, Sakamoto T, Matsuo Y, Mizowaki T. Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy. Med Phys. 2021; 48: 1781-1791.
   3. Aizawa R, Takayama K, Nakamura K, Ogata T, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Tashiro Y, Ota H, Ogawa O, Mizowaki T. Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy. Int J Urol. 2021; 28:749-755.
   4. Aizawa R, Nakamura K, Norihisa Y, Ogata T, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T.Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up. Int J Clin Oncol. 2021; 26 2113-2122.
   5. Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer. Urol Oncol. 2021; 39: 131 e9-e15.
   6. Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, Mizusawa J, Sekino Y, Ono T, Aoyama H, Satomi K, Ichimura K, Kinoshita M, Ohno M, Ito Y, Nishikawa R, Fukuda H, Nishimura Y, Narita Y, Brain Tumor Study Group and Radiation Therapy Study Group of the Japan Clinical Oncology Group. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC Cancer. 2021; 21: 1105 p1-8.
   7. Ashida R, Nakamura K, Aizawa R, Iramina H, Takayama K, Nakamura M, Mizowaki T. Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study. Jpn J Radiol. 2021; p1-9.
   8. Hanazawa H, Matsuo Y, Takeda A, Tsurugai Y, Iizuka Y, Kishi N, Takehana K, Mizowaki T. Development and validation of a prognostic model for non-lung cancer death in elderly patients treated with stereotactic body radiotherapy for non-small cell lung cancer. J Radiat Res. 2021; rrab093.
   9. Hiraoka S, Nakajima A, Kishi N, Takehana K, Hanazawa H, Matsuo Y, Mizowaki T. Efficacy of local salvage therapy for recurrent uterine cervical cancer after definitive radiotherapy. Int J Clin Oncol. 2021; 26 1968-1976.
   10. Hirashima H, Nakamura M, Mukumoto N, Ashida R, Fujii K, Nakamura K, Nakajima A, Sakanaka K, Yoshimura M, Mizowaki T. Reducing variability among treatment machines using knowledge-based planning for head and neck, pancreatic, and rectal cancer. J Appl Clin Med Phys. 2021;22 245-254.
   11. Hirashima H, Nakamura M, Baillehache P, Fujimoto Y, Nakagawa S, Saruya Y, Kabasawa T, Mizowaki T. Development of in-house fully residual deep convolutional neural network-based segmentation software for the male pelvic CT. Radiat Oncol. 2021; 22 135.
   12. Hirata K, Narabayashi M, Hanai Y, Fukumoto K, Kosuga T, Tanaka K, Mukumoto N, Ohtsu S. Comparison of thoracic and abdominal deep inspiration breath holds in whole-breast irradiation for patients with left-sided breast cancer.  Breast Cancer. 2021; 28 1154-1162.
   13. Ino A, Sakanaka K, Inoo H, Ishida Y, Kanda J, Mizowaki T. Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation. Int Cancer conf J. 2021; 10 p1-6.
   14. Inoue M, Enomoto M, Yoshimura M, Mizowaki T. Pharmacological inhibition of sodium-calcium exchange activates NADPH oxidase and induces infection-independent NETotic cell death. Redox Biol. 2021; 43: 101983.
   15. Iramina H, Nakamura M, Mizowaki T. Actual delivered dose calculation on intra-irradiation cone-beam computed tomography images: a phantom study. Phys Med Biol. 2021; 66: 015007.
   16. Kakino R, Nakamura M, Hu N, Iramina H, Tanaka H, Sakurai Y, Mizowaki T. Photoneutron-induced damage reduction for cardiac implantable electronic devices using neutron-shielding sheets in high-energy X-ray radiotherapy: A phantom study. Phys Med. 2021; 89: p151-159.
   17. Kawamura M, Araki N, Kishi N, Suwa T, Yamamoto Y, Kanai O, Fujita K, Okamura M, Nakatani K, Mio T. Retrospective Treatment Outcomes of Concurrent Chemoradiotherapy in Patients with Stage III Non-small Cell Lung Cancer at a Single Institution: The Pre-PACIFIC Era. Japanese J. Lung Cancer. 2021; 61: 383-388.
   18. Kawamura M, Yoshimura M, Shimizu Y, Sano K, Ishimori T, Nakamoto Y, Mizowaki T, Hiraoka M. Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with (18)F-Fluoromisonidazole-PET/CT. Mol Imaging Biol, 2021; 23: 597-603.
   19. Kosaka T, Uto M, Hiraoka S, Kato I, Umeda K, Hiramatsu H, Sakamoto A, Takita J, Mizowaki T. Radiation recall myositis caused by pazopanib in a patient with refractory osteosarcoma. Pediatric Blood & Cancer. 2021; 68 e29147.
   20. Matsuo Y, Nagata Y, Wakabayashi M, Ishikura S, Onishi H, Kokubo M, Karasawa
       K, Shioyama Y, Onimaru R, Hiraoka M.  Impact of pre-treatment C-reactive
       protein level and skeletal muscle mass on outcomes after stereotactic body
       radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis
       of the Japan Clinical Oncology Group study JCOG0403. J Radiat Res. 2021; 62: 901-909.
   21. Murakami N, Mori T, Machida R, Kodaira T, Ito Y, Shikama N, Konishi K, Matsumoto Y, Murakami Y, Nakamura N. Prognostic Value of Epithelial Cell Adhesion Molecules in T1‐2N0M0 Glottic Cancer. Laryngoscope. 2021; 131: 1522-1527.
   22. Nakamura M, Nakao M, Mukumoto N, Ashida R, Hirashima H, Yoshimura M, Mizowaki T. Statistical shape model-based planning organ-at-risk volume: application to pancreatic cancer patients. Phys Med Biol. 2021; 66: 014001.
   23. Nakao M, Nakamura M, Mizowaki T, Matsuda T. Statistical deformation reconstruction using multi-organ shape features for pancreatic cancer localization. Med Image Anal. 2021; 67: 101829.
   24. Ono Y, Yoshimura M, Ono T, Fujimoto T, Miyabe Y, Matsuo Y, Mizowaki T. Appropriate margin for planning target volume for breast radiotherapy during deep inspiration breath-hold by variance component analysis. Radiat Oncol. 2021; 16: 49.
   25. Sakanaka K, Fujii K, Hirashima H, Mukumoto N, Inoo H, Narukami R, Sakai Y, Mizowaki T. Chemoradiotherapy for fistula-related perianal squamous cell carcinoma with Crohn’s disease. Int Cancer Conf J. 2021; 10: 305-311.
   26. Sakanaka K, Ishida Y, Fujii K, Ishihara Y, Nakamura M, Hiraoka M, Mizowaki T. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study. Clin Oncol. 2021; 33: 191-201.
   27. Sato GE, Matsuo Y, Kanemitsu H, Minatoya K, Nakajima D, Date H, Nkagawa Y, Mizowaki T. Safe Delivery of Postoperative Radiotherapy for Thymic Carcinoma Located on the Outflow Graft of a Left Ventricular Assist Device. JTO Clinical and Research Reports. 2021; 2:100101.
   28. Shintani T, Kishi, N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Narabayashi M, Ishida Y, Sakamoto M, Fujishiro S, Katagiri T, Kim YH, Mizowaki T. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab. Clin Lung Cancer. 2021; 22(5): 401-410.
   29. Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M and Japanese Urological Oncology Group. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2021; 112: 1524-1533.
   30. Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y Takahashi A, kimura T, Tabata K, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M and Japanese Urological Oncology Group.. Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer. Cancer Sci. 2021; 112: 3616-3626.
   31. Suwa T, Kobayashi M, Nam JM, Harada H. Tumor microenvironment and tumor radioresistance. Experimental & Molecular Medicine. 2021; 53: 1029-1035.
   32. Suwa T, Kobayashi M, Shirai Y, Tabuchi Y, Takeda N, Akamatsu S, Ogawa O, Mizowaki T, Hammond E, and Harada H. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization. JCI insight. 2021; 6: e148135.
   33. Suwa T, Ishida Y, Negoro Y, Kusumi F, Kadokawa Y, Aizawa R, Nakajima T, Okamoto Y, Okuno Y, Yamada K,  Ogura M, Murakami M, and Mizowaki T. Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma, Clin Transl Radiat Oncol. 2021; 30: 88-94.
   34. Takehana K, Nakamura D, Abdelghaffar A, Uto M, Katagiri T, Arakawa Y, Mineharu Y, Miyamoto S, Mizowaki T. Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy. Eur Radiol. 2021; 31 6367-6373.
   35. Takeno S, Tanaka H, Watanabe T, Mizowaki T, Suzuki M. Quantitative autoradiography in boron neutron capture therapy considering the particle ranges in the samples. Phys Med. 2021; 82: 306-320.
   36. Torizuka D, Uto M, Takehana K, Mizowaki T. Dosimetric comparison among dynamic conformal arc therapy, coplanar and non-coplanar volumetric modulated arc therapy for single brain metastasis. J Radiat Res. 2021; rrab092.
   37. Tsuruta Y, Nakata M, Nakamura M, Uto M, Takehana K, Hirashima H, Fujimoto T, Mizowaki T.  Evaluation of intrafractional head motion for intracranial stereotactic radiosurgery with a thermoplastic frameless mask and ceiling-floor-mounted image guidance device. Phys Med. 2021; 81: 245-252.
   38. Uto M, Ogura K, Katagiri T, Takehana K, Mizowaki T. Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy. Radiat Oncol. 2021; 16:140.
   39. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H. Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2021; 28.
   40. Yamamoto T, Niibe Y, Aoki M, Onishi H, Yamada K, Shintani T, Yamashita H, Kobayashi M, Oh R, Jingu K. Stereotactic body radiotherapy for pulmonary oligometastases as an initial metastasis‐directed therapy: patterns of relapse and predictive factors for early mortality. Precis Radiat Oncol. 2021;5(2):84-92. doi:10.1002/pro6.1115

   2020

   1. Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol. 2020; 25:713-719.
   2. Ashida R, Nakamura M, Yoshimura M, Mizowaki T. Impact of interfractional anatomical variation and setup correction methods on interfractional dose variation in IMPT and VMAT plans for pancreatic cancer patients: A planning study. J Appl Clin Med Phys. 2020; 21:49-59.
   3. Fujii K, Sakanaka K, Uozumi R, Ishida Y, Inoo H, Tsunoda S, Miyamoto S, Muto M, Mizowaki T. Association of Chemoradiotherapy With Thoracic Vertebral Fractures in Patients With Esophageal Cancer. JAMA Netw Open. 2020; 3: e2013952. 
   4. Hiraoka M, Mizowaki T, Matsuo Y, Nakamura M, Verellen D. The gimbaled-head radiotherapy system: Rise and downfall of a dedicated system for dynamic tumor tracking with real-time monitoring and dynamic WaveArc. Radiother Oncol. 2020; 153: 311-318.
   5. Hiraoka S, Sakanaka K, Iwai T, Fujii K, Inoo H, Mizowaki T. Therapy-Related Acute Myeloid Leukemia 2 Months after Chemoradiotherapy for Esophageal Cancer: A Case Report. Case Rep Oncol. 2020; 13:299-303.
   6. Hirashima H, Ono T, Nakamura M, Miyabe Y, Mukumoto N, Iramina H, Mizowaki T. Improvement of prediction and classification performance for gamma passing rate by using plan complexity and dosiomics features. Radiother Oncol. 2020; 153: 250-257.
   7. Iizuka Y, Katagiri T, Ogura K, Inoue M, Nakamura K, Mizowaki T. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer. Ann Nucl Med. 2020; 34:736-741.
   8. Iramina H, Nakamura M, Mizowaki T. Direct measurement and correction of both megavoltage and kilovoltage scattered x-rays for orthogonal kilovoltage imaging subsystems with dual flat panel detectors. J Appl Clin Med Phys. 2020; 21:143-154.
   9. Iramina H Nakamura M, Miyabe Y, Mukumoto N, Ono T, Hirashima H, Mizowaki T. Quantification and correction of the scattered X-rays from a megavoltage photon beam to a linac-mounted kilovoltage imaging subsystem. BLR|Open. 2020; 2: 20190048.
   10. Iramina H, Kitamura A, Nakamura M, Mizowaki T. Image quality evaluation of intra-irradiation cone-beam computed tomography acquired during one- and two-arc prostate volumetric-modulated arc therapy delivery: A phantom study. J Appl Clin Med Phys. 2020; 21: 231-239.
   11. Ito H, Matsuo Y, Ohtsu S, Nishimura T, Terada Y, Sakamoto T, Mizowaki T. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. Int J Clin Oncol. 2020. 25:274-281.
   12. Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, Shibuya K, Kanai M, Masui T, Fukuda A, Isoda H, Hiraoka M, Mizowaki T. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiat Oncol. 2020. 15: 264.
   13. Kakino R, Nakamura M, Mitsuyoshi T, Shintani T, Hirashima H, Matsuo Y, Mizowaki T. Comparison of radiomic features in diagnostic CT images with and without contrast enhancement in the delayed phase for NSCLC patients. Phys Med. 2020; 69:176-182.
   14. Kakino R, Nakamura M, Mitsuyoshi T, Shintani T, Kokubo M, Negoro Y, Fushiki M, Ogura M, Itasaka S, Yamauchi C, Otsu S, Sakamoto T, Sakamoto M, Araki N, Hirashima H, Adachi T, Matsuo Y, Mizowaki T. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study. Med Phys. 2020; 47: 4634-4643.
   15. Kawamura M, Yoshimura M, Nakamura M, Ishihara Y, Mukumoto N, Hirashima H, Iramina H, Hiraoka M, Mizowaki T. Radiotherapy planning techniques to reduce lung irradiation in head and neck cancer patients with mediastinal involvement. Radiol Phys Technol. 2020; 13: 128-135.
   16. Kishi N, Nakamura M, Hirashima H, Mukumoto N, Takehana K, Uto M, Matsuo Y, Mizowaki T. Validation of the clinical applicability of knowledge-based planning models in single-isocenter volumetric-modulated arc therapy for multiple brain metastases. J Appl Clin Med Phys. 2020; 21: 141-150.
   17. Matsushita N, Nakamura M, Sasaki M, Yano S, Yoshimura M, Mizowaki T. Analyses of integrated EPID images for on-treatment quality assurance to account for interfractional variations in volumetric modulated arc therapy. J Appl Clin Med Phys. 2020; 21: 110-116.
   18. Miyamae Y, Akimoto M, Sasaki M, Fujimoto T, Yano S, Nakamura M. Variation in target volume and centroid position due to breath holding during four-dimensional computed tomography scanning: A phantom study. J Appl Clin Med Phys. 2020; 21: 11-17.
   19. Murakami Y, Noda SE, Hatayama Y, Maebayashi T, Jingu K, Nagata Y, Mizowaki T. What motivated medical students and residents to become radiation oncologists in Japan?-Questionnaire report by the radiotherapy promotion committee of JASTRO. J Radiat Res. 2020; 61: 727-732.
   20. Niibe Y, Yamamoto T, Onishi H, Yamashita H, Katsui K, Matsumoto Y, Oh RJ, Aoki M, Shintani T, Yamada K, Kobayashi M, Ozaki M, Manabe Y, Yahara K, Nishikawa A, Kakuhara H, Yamamoto K, Inoue T, Takada YU, Nagata K, Suzuki O, Terahara A, Jingu K. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. Anticancer Res. 2020;40(1):393-399. doi:10.21873/anticanres.13965
   21. Nishimura Y, Ishikura S, Shibata T, Kodaira T, Ito Y, Tsuchiya K, Murakami Y, Saitoh JI, Akimoto T, Nakata K, Yoshimura M, Teshima T, Toshiyasu T, Ota Y, Ishikawa K, Shimizu H, Minemura T, Nakamura K, Hiraoka M. A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015). Int J Clin Oncol. 2020; 25: 1250-1259.
   22. Nishizaki D, Hoshino N, Hida K, Nishikawa Y, Horimatsu T, Minamiguchi S, Sakanaka K, Sakai Y. Nonsurgical Management Following Local Resection for Early Rectal Cancer in Patients with High-risk Factors: A Single-institute Experience. J Anus Rectum colon. 2020; 4: 174-180.
   23. Okabayashi S, Matsuo Y, Kishi N, Hanazawa H, Mizowaki T. Dynamic tumor-tracking stereotactic body radiation therapy for a solitary tumor in a transplanted organ: two case reports. Int Cancer Conf J. 2020; 9: 221-226.
   24. Ono T, Mitsuyoshi T, Shintani T, Tsuruta Y, Iramina H, Hirashima H, Miyabe Y, Nakamura M, Matsuo Y, Mizowaki T. Independent calculation-based verification of volumetric-modulated arc therapy-stereotactic body radiotherapy plans for lung cancer. J Appl Clin Med Phys. 2020; 21:135-143.
   25. Sakanaka K, Fujii K, Mizowaki T. Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report. BMC Cancer. 2020; 20:p21.
   26. Sakanaka K, Mizowaki T. A Case Report of a Solitary Pelvic Mass Proven to Be a Lymph Nodal Metastasis from Anal Cancer. Case Rep Oncol. 2020; 13: 164-169.
   27. Sasaki M, Nakamura M, Ono T, Ashida R, Yoshimura M, Nakata M, Mizowaki T, Sugimoto N. Positional repeatability and variation in internal and external markers during volumetric-modulated arc therapy under end-exhalation breath-hold conditions for pancreatic cancer patients. J Radiat Res. 2020; 61: 755-765.
   28. Sato GE, Aizawa R, Nakamura K, Takayama K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer. J Radiat Res. 2020; 61:622-628.
   29. Shintani T, Nakamura M, Matsuo Y, Miyabe Y, Mukumoto N, Mitsuyoshi T, Iizuka Y, Mizowaki T. Investigation of 4D dose in volumetric modulated arc therapy-based stereotactic body radiation therapy: does fractional dose or number of arcs matter? J Radiat Res. 2020; 61:325-334.
   30. Tasaka K, Umeda K, Kamitori T, Ogata H, Mikami T, Saida S, Kato I, Hiramatsu H, Arakawa, Y, Uto M, Mizowaki T, Yoshizawa A, Adachi S, Takita J. Intracranial Growing Teratoma Syndrome With Intraventricular Lipid Accumulation. J Pediatr Hematol Oncol. 2020; 43: E505-E507.
   31. Uchida Y, Masui T, Nagai K, Anazawa T, Yoshimura M, Uza N, Takaori K, Mizowaki T, Uemoto S. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis. Surg Oncol. 2020; 35: 527-532.
   32. Watanabe T, Firat E, Scholber J, Gaedicke S, Heinrich C, Luo R, Ehrat N, Multhoff G, Schmitt-Graeff A, Grosu AL, Abdollahi A, Hassel JC, von Bubnoff D, Meiss F, Niedermann G. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother. 2020; 69:1823-1832.
   33. Watanabe T, Gaedicke S, Guffart E, Firat E, Niedermann G. Adding indoximod to hypofractionated radiotherapy with anti-PD-1 checkpoint blockade enhances early NK and CD8+ T cell-dependent tumor activity. Clin Cancer Res. 2019; 26: 945-956.
   34. Yamanashi K, Hamaji M, Matsuo Y, Kishi N, Chen-Yoshikawa TF, Mizowaki T, DateH. Updated long-term outcomes of salvage surgery after stereotactic body radiotherapy for early-stage non-small-cell lung cancer. Interract Cardiovasc Thorac Surg. 2020; 31: 982-984.
   35. Yamamoto T, Niibe Y, Aoki M, Shintani T, Yamada K, Kobayashi M, Yamashita H, Ozaki M, Manabe Y, Onishi H, Yahara K, Nishikawa A, Katsui K, Oh RJ, Terahara A, Jingu K. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival. BMC Cancer. 2020;20(1):997. doi:10.1186/s12885-020-07514-9
   36. Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, Oh RJ, Shintani T, Yahara K, Ozaki M, Manabe Y, Jingu K. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. J Radiat Res. 2020;61(6):935-944. doi:10.1093/jrr/rraa071
   37. Yamamoto T, Niibe Y, Matsumoto Y, Aoki M, Oh RJ, Ozaki M, Kobayashi M, Manabe Y, Shintani T, Dekura Y, Onishi H, Yamashita H, Jingu K. Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases. Cancer Med. 2020;9(23):8902-8911. doi:10.1002/cam4.3508
   38. Yoshida H, Nagai H, Sakamori Y, Ozasa H, Nishimura T, Tomii K, Hirai T, Matsuo Y, Iizuka Y, Mizowaki T, Yoshimura K, Kim YH. Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer. In Vivo. 2020;34(2):897-902.

   2019

   1. Aibe N, Karasawa K, Aoki M Akahane K, Ogawa Y, Ogo E, Kanamori S, Kawamori J, Saito AI, Shiraishi K, Sekine H, Tachiiri S, Yoshimura M, Yamauchi C. Results of a nationwide survey on Japanese clinical practice in breast-conserving radiotherapy for breast cancer. J Radiat Res. 2019; 60:141-149.
   2. Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol. 2019; 24:1247-1255.
   3. Hirashima H, Nakamura M, Miyabe Y, Mukumoto N, Ono T, Iramina H, Mizowaki T. Quality assurance of non-coplanar, volumetric-modulated arc therapy employing a C-arm linear accelerator, featuring continuous patient couch rotation. Radiat Oncol. 2019; 14: 62 (1-10).
   4. Hamaji M, Matsuo Y, Chen-Yoshikawa TF, Mizowaki T, Date H. Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses. J Thorac Dis. 2019;11(Suppl 13):S1646-S1652.
   5. Iizuka Y, Ohashi M, Kawasaki S, Nakai I, Mizowaki T. Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer: A Case Report. Kaku Igaku. 2019; 56: 117-120.
   6. Iizuka Y, Nakamura M, Kozawa S, Mitsuyoshi T, Matsuo Y, Mizowaki T. Tumour volume comparison between 16-row multi-detector computed tomography and 320-row area-detector computed tomography in patients with small lung tumours treated with stereotactic body radiotherapy: Effect of respiratory motion. Eur. J. Radiol. 2019; 117:120-125.
   7. Iizuka Y, Katagiri T, Ogura K, Mizowaki T. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer. Ann. Nucl. Med. 2019; 33: 495-501.
   8. Ishida Y, Sakanaka K, Fujii K, Itasaka S, Mizowaki T. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome. J Radiat Res. 2019; 60: 517-526.
   9. Kawamura M, Yoshimura M, Asada H, Nakamura M, Matsuo Y, Mizowaki T. A scoring system predicting acute radiation dermatitis in patients with head and neck cancer treated with intensity-modulated radiotherapy. Radiat Oncol. 2019; 14: 1-14.
   10. Matsuo Y. Sarcopenia is a potential factor for optimized treatment selection for elderly patients with early stage non-small cell lung cancer. J Thorac Dis. 2019;11: S443-445.
   11. Matsuo Y. Stereotactic body radiotherapy as an alternative to metastasectomy for pulmonary oligometastasis J Thorac Dis. 2019;11: S1420-1422.
   12. Nakamura M, Nakao M, Hirashima H, Iramina H, Mizowaki T. Performance evaluation of a newly developed three-dimensional model-based global-to-local registration in prostate cancer. J Radiat Res. 2019; 60: 595-602.
   13. Ono T, Hirashima H, Iramina H, Mukumoto N, Miyabe Y, Nakamura M, Mizowaki T. Prediction of dosimetric accuracy for VMAT plans using plan complexity parameters via machine learning. Med. Phys. 2019; 46: 3823-3832.
   14. Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiat. Oncol. 2019; 14: 121 (pp1-8).
   15. Sakanaka K, Ishida Y, Mizowaki T. A Case Report of Locally Advanced Anal Cancer with Solitary Cutaneous Nodular Metastasis in the Ipsilateral Labia Majora Treated with Definitive Chemoradiotherapy. Case Rep Oncol. 2019; 12: 721-727.
   16. Sakanaka K, Fujii K, Ishida Y, Miyamoto S, Horimatsu T, Muto M, Mizowaki T. Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma. Cancer Manag Res. 2019; 11: 3623-3630.
   17. Sasaki M, Nakamura M, Mukumoto N, Goto Y, Ishihara Y, Nakata M, Sugimoto N, Mizowaki T. Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases. J Appl Clin Med Phys. 2019; 20: 118-126.
   18. Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K, Ogawa H, Ogawa T, Sakanaka K, Sakamoto T, Kato K, Kitagawa Y. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019; 49: 1055-1060.
   19. Uto M, Ogura K, Mukumoto N, Miyabe Y, Nakamura M, Hirashima H, Katagiri T, Takehana K, Hiraoka M, Mizowaki T. Single-isocenter volumetric-modulated Dynamic WaveArc therapy for two brain metastases. Jpn. J. Radiol. 2019; 37: 619-625.
   20. Zieglar M, Nakamura M, Hirashima H, Ashida R, Yoshimura M, Bert C, Mizowaki T. Accumulation of the delivered treatment dose in VMAT with breath-hold for pancreatic cancer patients based on daily CBCT images with limited field-of-view. Med Phys. 2019; 46: 2969-2977.

   2018

   1. Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T. Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2018; 23:749-756.
   2. Aizawa R, Uto M, Takehana K, Arakawa Y, Miyamoto S, Mizowaki T. Radiation-induced cystic brain necrosis developing 10 years after linac-based stereotactic radiosurgery for brain metastasis. Oxf Med Case Reports. 2018; 11: 387-390.
   3. Chen Z, Takehana K, Mizowaki T, Uto M, Ogura K, Sakanaka K, Arakawa Y, Mineharu Y, Miyabe Y, Mukumoto N, Miyamoto S, Hiraoka M. Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation. Int J Clin Oncol. 2018; 23: 608-614.
   4. Goto Y, Ashida R, Nakamura A, Itasaka S, Shibuya K, Akimoto M, Mukumoto N, Matsumoto S, Kanai M, Isoda H, Masui T, Kodama Y, Nakamura M, Takaori K, Mizowaki T, Hiraoka M. Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. Oncotarget. 2018; 9: 23628-35.
   5. Goto Y, Nakamura A, Ashida R, Sakanaka K, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Isoda H, Masui T, Kodama Y, Takaori K, Hiraoka M, Mizowaki T. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2018; 13: 1-9.
   6. Hamaji M, Mitsuyoshi T, Yoshizawa A, Sato T, Matsuo Y, Chen-Yoshikawa TF, Sonobe M, Mizowaki T, Date H. Salvage Pulmonary Metastasectomy for Local Relapse After Stereotactic Body Radiotherapy. Ann Thorac Surg. 2018;105:e165-e168.
   7. Hirashima H, Miyabe Y, Nakamura M, Mukumoto N, Mizowaki T, Hiraoka M. Quality assurance of geometric accuracy based on an electronic portal imaging device and log data analysis for Dynamic WaveArc irradiation. J Appl Clin Med Phys. 2018; 19: 234-242.
   8. Hirashima H, Nakamura M, Ishihara Y, Mukumoto N, Akimoto M, Tomita T, Hirose Y, kitsuda K, Ishigaki T, Mizowaki T. Comparison of Gamma Pass Rate between the Dose-to-Water and Dose-to-Medium Reporting Modes for Patient-Specific QA Using a Helical Diode Array Dosimeter with a Fixed Phantom Density. Int J Med Phys Clin Eng Radiat Oncol. 2018;7:74-86.
   9. Hirashima H, Nakamura M, Miyabe Y, Uto M, Nakamura K, Mizowaki T. Monitoring of mechanical errors and their dosimetric impact throughout the course of non-coplanar continuous volumetric-modulated arc therapy. Radiat Oncol. 2018;13:1-8.
   10. Inoue M, Nakashima R, Enomoto M, Koike Y, Zhao X, Yip K, Huang SH, Waldron JN, Ikura M, Liu FF, Bratman SV. Plasma redox imbalance caused by albumin oxidation promotes lung-predominant NETosis and pulmonary cancer metastasis. Nat Commun. 2018;9:5116.
   11. Inoue T, Mizowaki T, Kabata D, Shintani A, Terada N, Yamasaki T, Negoro H, Kobayashi T, Nakamura K, Inokuchi H, Ogawa O. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study. Clin Genitourin Cancer. 2018;16:135-141.
   12. Inoue T, Katoh N, Ito YM, Kimura T, Nagata Y, Kuriyama K, Onishi  H, Yoshitake T, Shioyama Y, Iizuka Y, Inaba K, Konishi K, Kokubo M, Karasawa K, Kozuka T, Tanaka K, Sakakibara-Konishi J, Kinoshita I, Shirato H. Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study. Lung Cancer. 2018;122:107-112.
   13. Iramina H, Nakamura M, Iizuka Y, Mitsuyoshi T, Matsuo Y, Mizowaki T, Kanno I. Optimization of training periods for the estimation model of three-dimensional target positions using an external respiratory surrogate. Radiat Oncol. 2018;13:1-12.
   14. Iramina H, Hamaguchi T, Nakamura M, Mizowaki T, Kanno I. Metal artifact reduction by filter-based dual-energy cone-beam computed tomography on a bench-top micro-CBCT system: concept and demonstration. J Radiat Res. 2018;59:511-20.
   15. Iramina H, Nakamura M, Mizowaki T, Kanno I. Effective Atomic Number Measurement with Energy-Resolved Computed Tomography Using Two-Dimensional “transXend” Int J Med Phys Clin Eng Radiat Oncol. 2018;07:61-73.
   16. Ishida Y, Sakanaka K, Itasaka S, Nakamoto Y, Togashi K, Mizowaki T, Hiraoka M. Effect of long fasting on myocardial accumulation in 18F-fluorodeoxyglucose positron emission tomography after chemoradiotherapy for esophageal carcinoma. J Radiat Res. 2018;59:182-9.
   17. Katagiri T, Kobayashi M, Yoshimura M, Morinibu A, Itasaka S, Hiraoka M, Harada H. HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by upregulating expression and secretion of Sonic hedgehog. Oncotarget. 2018;9:10525-10535.
   18. Kayama T, Sato S, Sakurada K, et al. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018; JCO2018786186.
   19. Kubota H, Umeda K, Kagehiro K, Tanaka K, Daifu T, Hamabata T, Nodomi S, Kato I, Hiramatsu H, Arakawa Y, Mizowaki T, Adachi S. High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma. Pediatr Blood Cancer. 2018;65:e27104.
   20. Mackenzie L, Carey, M, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D’Este C, Yoshimura M, Toi M. Agreement between patients’ and radiation oncologists’ cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. PLoS One. 2018;13:e0198437.
   21. Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D’Este C, Sanson-Fisher R. A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. Psychooncology. 2018;27:1840-1846.
   22. Matsuo Y. A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2018;7:S111-S113.
   23. Matsuo Y. A Systematic Literature Review on Salvage Radiotherapy for Local or Regional Recurrence After Previous Stereotactic Body Radiotherapy for Lung Cancer. Technol Cancer Res Treat. 2018;17:1533033818798633.
   24. Matsuo Y, Mitsuyoshi T, Shintani T, Iizuka Y, Mizowaki T. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer. J Geriatr Oncol. 2018; 9: 589-93.
   25. Mitsuyoshi T, Matsuo Y, Itou H, Shintani T, Iizuka Y, Kim YH, Mizowaki T. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. J Radiat Res. 2018;59:50-57.
   26. Mitsuyoshi T, Matsuo Y, Shintani T, Iizuka Y, Ueki N, Nakamura M, Mizowaki T. Pilot Study of the Safety and Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumors. Clin Lung Cancer. 2018;19:e287-e296.
   27. Mizowaki T. ADT in combination with radiation therapy for clinically localized prostate cancer. Springer. Editor: Arai Y and Ogawa O. 2018;12:99-112.
   28. Nakamura A, Hiraoka M, Itasaka S, Nakamura M, Akimoto M, Ishihara Y, Mukumoto N, Goto Y, Kishi T, Yoshimura M, Matsuo Y, Yano S, Mizowaki T. Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. Sci Rep. 2018; 8. 17096(pp1-10).
   29. Nakamura M, Ishihara Y, Matsuo Y, Iizuka Y, Ueki N, Iramina H, Hirashima H, Mizowaki T. Quantification of the kV X-ray imaging dose during real-time tumor tracking and from three- and four-dimensional cone-beam computed tomography in lung cancer patients using a Monte Carlo simulation. J Radiat Res. 2018;59:173-181.
   30. Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Int J Clin Oncol. 2018:23;158-164.
   31. Nakamura K, Ikeda I, Inokuchi H, Takayama K, Inoue T, Kamba T, Ogawa O, Hiraoka M, Mizowaki T. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. J Radiat Res. 2018;59:656-63.
   32. Nomura M, Otsuka A, Yoshimura M, Nonomura Y, Kaku Y, Matsumoto S, Muto M. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. Cancer Chemother Pharmacol. 2018;81:823-827.
   33. Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study. Cancers (Basel). 2018;10:257.
   34. Onishi H, Marino K, Yamashita H, et al. Case Series of 23 Patients Who Developed Fatal Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer. Technol Cancer Res Treat. 2018;17:1533033818801323.
   35. Onimaru R, Onishi H, Ogawa G et al. Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). Jpn J Clin Oncol. 2018;48:1076-1082.
   36. Ono T, Miyabe Y, Takahashi K, Akimoto M, Mukumoto N, Ishihara Y, Nakamura M, Mizowaki T, Hiraoka M. Geometric and dosimetric accuracy of dynamic tumor tracking during volumetric-modulated arc therapy using a gimbal mounted linac. Radiother Oncol. 2018; 129: 166-172.
   37. Ono T, Miyabe Y, Akimoto M, Mukumoto N, Ishihara Y, Nakamura M, mizowaki T. Development of a portable quality control application using a tablet-type electronic device. Med Phys. 2018;45:1029-1035.
   38. Ono Y, Yoshimura M, Hirata K, Ono T, Hirashima H, Mukumoto N, Nakamura M, Inoue M, Hiraoka M, Mizowaki T. Dosimetric advantages afforded by a new irradiation technique, Dynamic WaveArc, used for accelerated partial breast irradiation. Physica Medica. 2018;48:103-110.
   39. Sakanaka K, Ishida Y, Fujii K, Itasaka S, Miyamoto S, Horimatsu T, Muto M, Mizowaki T. Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma. Radiat Oncol. 2018;13:1-7.
   40. Sasaki M, Nakamura M, Mukumoto N, Nakata M, Hiraoka M. Dosimetric impact of translational and rotational setup errors for spine stereotactic body radiotherapy: A phantom study. Med Dosim. 2018; 43: 320-6.
   41. Shintani T, Matsuo Y, Iizuka Y, Mitsuyoshi T, Mizowaki T. A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence. Int J Radiat Oncol Biol Phys. 2018;100:1228-1236.
   42. Shioyama Y, Onishi H, Takayama K, et al. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database. Technol Cancer Res Treat. 2018;17:1533033818783904.
   43. Takahashi S, Kinuya S, Nonomura N, Shinohara N, Suzuki K, Suzuki H, Nakamura K, Satoh T, Tateishi U, Yoneda T, Horikoshi H, Igawa T, Kamai T, Koizumi M, Kosaka T, Matsubara N, Miyake H, Mizokami A, Mizowaki T, Nakamura N, Nozawa M, Takahashi T, Uemura H, Uemura M, Yokomizo A, Yoshimura M, Kakehi Y. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases. Oncol Ther. 2018; 6:157-171.
   44. Uto M, Mizowaki T, Ogura K, Mukumoto N, Katagiri T, Takehana K, Hiraoka M. Dosimetric comparison between dual-isocentric dynamic conformal arc therapy and monoisocentric volumetric-modulated arc therapy for two large brain metastases. J Radiat Res. 2018; 59: 774-81.
   45. Yamada K, Chigusa Y, Nomura M, Sakanaka K, Nakamura M, Yano S, Tsunoda S, Kondoh E, Mandai M. A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy,” Case Reports in Obstetrics and Gynecology.”. Case Rep. Obstet. Gynecol. 2018; 2018: 1280582(1-6).

   2017

   1. Aizawa R, Matsumoto S, Uneno Y, Nishikawa Y, Ozaki Y, Mori Y, Kanai M, Ishida Y, Sakanaka K, Hiraoka M. Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer. Jap J Clin Oncol. 2017;47: 885-888.
   2. Aizawa R, Sakamoto M, Orito N, Kono M, Ogura M, Negoro Y, Sagoh T, Tsukahara K, Komatsu K, Noguchi M. The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients. Anticancer Res. 2017;37:5761-5766.
   3. Akimoto M, Nakamura M, Nakamura A, Mukumoto N, Kishi T, Goto Y, Mizowaki T, Hiraoka M. Inter-and intrafractional variation in the three-dimensional positions of pancreatic tumors due to respiration under real-time monitoring. Int J Radiat Oncol Biol Phys. 2017;98:1204-1211.
   4. Goto Y, Koyasu S, Kobayashi M, Harada H. The emerging roles of the ubiquitination/deubiquitination system in tumor radioresistance regarding DNA damage responses, cell cycle regulation, hypoxic responses, and antioxidant properties: Insight into the development of novel radiosensitizing strategies. Mutation Res. 2017; 76-81.
   5. Hirashima H, Nakamura M, Miyabe Y, Mukumoto N, Uto M, Nakamura K, Mizowaki T, Hiraoka M. Geometric and dosimetric quality assurance using logfiles and a 3D helical diode detector for Dynamic WaveArc. Phys Med. 2017;43:107-13.
   6. Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. J Radiat Res. 2017;58:79-85.
   7. Hirata K, Yoshimura M, Mukumoto N, Nakamura M, Inoue M, Sasaki M, Fujimoto T, Yano S, Nakata M, Mizowaki T. Three-dimensional intrafractional internal target motions in accelerated partial breast irradiation using three-dimensional conformal external beam radiotherapy. Radioth Oncol. 2017;124:118-123.
   8. Hussein M CE, Eaton D, Greer P, Howarth A, Ishikura S, Kry S, Lehmann J, Lye J, Monti A, Nakamura M, Hurkmans C, Clark C. A virtual dosimetry audit – towards transferability of gamma index analysis between clinical trial QA groups. Radiother Oncol. 2017;125:398-404.
   9. Iizuka Y, Matsuo Y, Nakamura M, Kozawa S, Ueki N, Mitsuyoshi T, Mizowaki T, Hiraoka M. Optimization of a newly defined target volume in fiducial marker-based dynamic tumor-tracking radiotherapy. Imag. in Radiat. Oncol. 2017;4:1-5.
   10. Inokuchi H, Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Nakamura K, Hiraoka M. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol. 2017;6:31-36.
   11. Ishihara Y, Nakamura M, Miyabe Y, Mukumoto N, Matsuo Y, Sawada A, Kokubo M, Mizowaki T, Hiraoka M. Development of a four-dimensional Monte Carlo dose calculation system for real-time tumor-tracking irradiation with a gimbaled X-ray head. Phys Med. 2017;35:59-65.
   12. Ito H, Itasaka S, Sakanaka K, Araki N, Mizowaki T, Hiraoka M. Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res. 2017;58:106-113.
   13. Iwai A, Umeda K, Uto M, Nihira H, Kawaguchi K, Mikami M, Nodomi S, Saida S, Hiramatsu H, Ogura K, Tanji M, Arakawa Y, Sakamoto T, Adachi S, Mizowaki T, Heike T. Whole brain radiotherapy with volumetric-modulated arc therapy for pediatric intracranial embryonic carcinoma prevents permanent alopecia. Pediatr Blood Cancer. 2017;64.
   14. Jingu K, Matsuo Y, Onishi H, Yamamoto T, Aoki M, Murakami Y, Yamashita H, Kakuhara H, Nemoto K, Sakayauchi T, Okamoto M, Niibe Y, Nagata Y, Ogawa K. Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer. Anticancer Res. 2017;37:2709-2713.
   15. Kimura T, Nagata Y, Harada H, Hayashi S, Matsuo Y, Takanaka T, Kokubo M, Takayama K, Onishi H, Hirakawa K, Shioyama Y, Ehara T. Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). Int J Clin Oncol. 2017;22:849-856.
   16. Mampuya WA, Matsuo Y, Nakamura A, Hiraoka M. Evaluation of the prevalence of burnout and psychological morbidity among radiation oncologist members of the Kyoto Radiation Oncology Study Group (KROSG). J Radiat Res. 2017;58:217-224.
   17. Hamaji M Chen-Yoshikawa TF, Matsuo Y, Motoyama H, Hijiya K, Menju T, Aoyama A, Sato T, Sonobe M, Date H. Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management. J Vis Surg. 2017;3.
   18. Matsuo Y, Shibuya K, Okubo K, Ueki N, Aoyama A, Sonobe M, Nakamura M, Mizowaki T, Date T, Hiraoka M. Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma. Acta Oncologica. 2017;56:957-62.
   19. Mukumoto N, Nakamura M, Akimoto M, Miyabe Y, Yokota K, Matsuo Y, Mizowaki T, Hiraoka M. Impact of sampling interval in training data acquisition on intrafractional predictive accuracy of indirect dynamic tumor-tracking radiotherapy. Med Phys. 2017;44:3899-3908.
   20. Nakashima R, Goto Y, Koyasu S, Kobayashi M, Morinibu A, Yoshimura M, Hiraoka M, Hammond EM, Harada H. UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Sci Rep. 2017;31.
   21. Nodomi S, Umeda K, Ueno H, Saida S, Hiramatsu H, Funaki T, Arakawa Y, Mizowaki T, Adachi S, Heike T. Efficacy of Ifosfamide-Cisplatin-Etoposide (ICE) Chemotherapy for a CNS Germinoma in a Child With Down Syndrome. J Pediat Hematol Oncol. 2017;39:39-42.
   22. Onimaru R, Onishi H, Shibata T, Hiraoka M, Ishikura S, Karasawa K, Matsuo Y, Kokubo M, Shioyama Y, Matsushita H, Ito Y, Shirato H. Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV100cc. Radiother Oncol. 2017;122:281-285.
   23. Ono T, Nakamura M, Hirose Y, Kitsuda K, Ono Y, Ishigaki T, Hiraoka M. Estimation of lung tumor position from multiple anatomical features on 4D-CT using multiple regression analysis. J Appl Clin Med Phys. 2017;18: 36-42.
   24. Sakanaka K, Itasaka S, Ishida Y, Fujii K, Horimatsu T, Mizowaki T, Sakai Y, Hiraoka M. Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. Radiat Oncol J. 2017;35:368-379.
   25. Shintani T, Matsuo Y, Iizuka Y, Mitsuyoshi T, Mizowaki T, Hiraoka M. Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. Anticancer Res. 2017;37:5161-5167.
   26. Shintani T, Matsuo Y, Iizuka Y, Mitsuyoshi T, Umeoka S, Nakamoto Y, Mizowaki T, Togashi K, Hiraoka M. Assessment of treatment response after lung stereotactic body radiotherapy using diffusion weighted magnetic resonance imaging and positron emission tomography: A pilot study. Eur J Radiol. 2017;92:58-63.
   27. Tsuruta Y, Nakamura M, Miyabe Y, Nakata M, Ishihara Y, Mukumoto N, Akimoto M, Ono T, Yano S, Higashimura K, Matsuo Y, Mizowaki T, Hiraoka M. Use of a second-dose calculation algorithm to check dosimetric parameters for the dose distribution of a first-dose calculation algorithm for lung SBRT plans. Phys Med. 2017;18:36-42.
   28. Uto M, Mizowaki T, Ogura K, Miyabe Y, Nakamura M, Mukumoto N, Hirashima H, Hiraoka M. Volumetric-modulated Dynamic WaveArc therapy reduces the dose to the hippocampus in patients with pituitary adenomas and craniopharyngiomas. Pract Radiat Oncol. 2017;7:382-387.
   29. Yamazaki H, Fushiki M, Mizowaki T, the Kansai Cancer Therapist Group. A surveillance study of the current status of reirradiation and patterns of practice. J Radiat Res. 2017;58:71-78.

   2016

   1. Burghelea M, Verellen D, Poels K, Hung C, Nakamura M, Dhont J, Gevaert, T, Van den Begin R, Collen C, Matsuo Y, Kishi T, Simon V, Hiraoka, M. de Ridder M. Initial characterization, dosimetric benchmark and performance validation of Dynamic Wave Arc. Radiat Oncol 2016;11:63(pp1-10).
   2. Colvill E, Booth J, Nill S, Fast M, Bedford J, Oelfke U, Nakamura M, Poulsen P, Worm E, Hansen R, Ravkilde T, Scherman Rydhog J, Pommer T, Munck Af Rosenschold P, Lang S, Guckenberger M, Groh C, Herrmann C, Verellen D, Poels K, Wang L, Hadsell M, Sothmann T, Blanck O, Keall P. A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking. Radiother Oncol 2016;119:159-65.
   3. Inokuchi H, Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Nakamura K, Nakamura M, Hiraoka M. Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma. Int J Clin Oncol 2016;21:156-61.
   4. Iramina H, Nakamura M, Iizuka Y, Mitsuyoshi T, Matsuo Y, Mizowaki T, Hiraoka M, Kanno I. The accuracy of extracted target motion trajectories in four-dimensional cone-beam computed tomography for lung cancer patients. Radiother Oncol 2016;121:46-51.
   5. Kishi T, Matsuo Y, Nakamura A, Nakamoto Y, Itasaka S, Mizowaki T, Togashi K, Hiraoka M. Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Radiother Oncol 2016;120:217-21.
   6. Kubota Y, Nakaigawa N. Committee for Establishment of the Clinical Practice Guideline for the Management of Bladder C, the Japanese Urological A. Essential content of evidence-based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update. Int J Urol 2016;23:640-5.
   7. Mampuya WA, Nakamura M, Hirose Y, Ishigaki T, Mizowaki T, Hiraoka M. Difference in dose‐volumetric data between the analytical anisotropic algorithm, the dose‐to‐medium, and the dose‐to‐water reporting modes of the Acuros XB for lung stereotactic body radiation therapy. J Appl Clin Med Phys 2016;17:1-7.
   8. Matsuo Y, Nakamura M, Mizowaki T, Hiraoka M. Introduction of variance component analysis to setup error analysis in radiotherapy. Med Phys 2016;43:5195-8.
   9. Mitsuyoshi T, Nakamura M, Matsuo Y, Ueki N, Nakamura A, Iizuka Y, Mampuya WA, Mizowaki T, Hiraoka M. Dosimetric comparison of lung stereotactic body radiotherapy treatment plans using averaged computed tomography and end-exhalation computed tomography images: Evaluation of the effect of different dose-calculation algorithms and prescription methods. Med Dosim 2016;41:305-9.
   10. Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer. Int J Clin Oncol 2016;21:783-90.
   11. Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. Int J Clin Oncol 2016;21:148-55.
   12. Mukumoto N, Nakamura M, Takahashi K, Miyabe Y, Kaneko S, Mizowaki T, Kokubo M, Hiraoka. Development of a four-axis moving phantom for patient-specific QA of surrogate signal-based tracking IMRT. Med Phys 2016;43:6364-74.
   13. Nakamura M, Minemura T, Ishikura S, Nishio T, Narita Y, Nishimura Y. An on-site audit system for dosimetry credentialing of intensity-modulated radiotherapy in Japanese Clinical Oncology Group (JCOG) clinical trials. Phys Med 2016;32:987-91.
   14. Ono T, Miyabe Y, Yokota K, Takahashi K, Akimoto M, Mukumoto N, Ishihara Y, Nakamura M, Mizowaki T, Hiraoka M. Development of a gimbal-swing irradiation technique for uniform expanded-field, wedged-beam, and intensity-modulated radiation therapy. Biomed Phys Eng Express 2016;2:065007(pp1-13).
   15. Sakanaka K, Ishida Y, Itasaka S, Ezoe Y, Aoyama I, Miyamoto S, Horimatsu T, Muto M, Hiraoka M. Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy. Int J Clin Oncol 2016;21:899-908.
   16. Takamiya M, Nakamura M, Akimoto M, Ueki N, Yamada M, Tanabe H, Matsuo Y, Mizowaki T, Kokubo M, Hiraoka M. Multivariate analysis for the estimation of target localization errors in fiducial marker‐based radiotherapy. Med Phys 2016;43:1907-12.
   17. Uto M, Mizowaki T, Ogura K, Arakawa Y, Mineharu Y, Miyamoto S, Hiraoka M. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma. International journal of clinical oncology 2016;21:1023-9.
   18. Uto M, Mizowaki T, Ogura K, Hiraoka M. Non-coplanar volumetric-modulated arc therapy (VMAT) for craniopharyngiomas reduces radiation doses to the bilateral hippocampus: a planning study comparing dynamic conformal arc therapy, coplanar VMAT, and non-coplanar VMAT. Radiat Oncol 2016;11:86(pp1-8).
   19. Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y, Tanaka H, Fukutani S, Masunaga S, Hiraoka M. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [18 F]-L-FBPA positron emission tomography in boron neutron capture therapy. BMC cancer 2016;16:859(pp1-10).
   20. Watanabe T, Tanaka H, Fukutani S, Suzuki M, Hiraoka M, Ono K. L-Phenylalanine preloading reduces the (10)B(n, alpha)(7)Li dose to the normal brain by inhibiting the uptake of boronophenylalanine in boron neutron capture therapy for brain tumours. Cancer Lett 2016;370:27-32.

   2015

   1. Akimoto M, Nakamura M, Miyabe Y, Mukumoto N, Yamada M, Tanabe H, Ueki N, Kaneko S, Matsuo Y, Mizowaki T, Kokubo M, Hiraoka M. Baseline correction of a correlation model for improving the prediction accuracy of infrared marker-based dynamic tumor tracking. J Appl Clin Med Phys. 2015;16:14-22.
   2. Akimoto M, Nakamura M, Miyabe Y, Mukumoto N, Yokota K, Mizowaki T, Hiraoka M. Long-term stability assessment of a 4D tumor tracking system integrated into a gimbaled linear accelerator. J Appl Clin Med Phys 2015;16:373-80.
   3. Gaowa A, Horibe T, Kohno M, Tabata Y, Harada H, Hiraoka M, Kawakami K. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers. Eur J Pharm Biopharm 2015; 92:228-36.
   4. Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M,Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, Harada H. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1alpha. Nature communications 2015;6:6153(pp1-13).
   5. Hirata K, Nakamura M, Yoshimura M, Mukumoto N, Nakata M, Ito H, Inokuchi H, Matsuo Y, Mizowaki T, Hiraoka M. Dosimetric evaluation of the Acuros XB algorithm for a 4 MV photon beam in head and neck intensity-modulated radiation therapy. J Appl Clin Med Phys. 2015;16:52-64.
   6. Iizuka Y, Matsuo Y, Ishihara Y, Akimoto M, Tanabe H, Takayama K, Ueki N, Yokota K, Mizowaki T, Kokubo M, Hiraoka M. Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac. Radiother Oncol 2015;117:496-500.
   7. Iizuka Y, Yoshimura M, Inokuchi H, Matsuo Y, Nakamura A, Mizowaki T, Hirano S, Kitamura M, Tateya I, Hiraoka M. Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx. Acta Otolaryngol 2015;135:96-102.
   8. Ikeda I, Mizowaki T, Ono T, Yamada M, Nakamura M, Monzen H, Yano S, Hiraoka M. Effect of intrafractional prostate motion on simultaneous boost intensity-modulated radiotherapy to the prostate: a simulation study based on intrafractional motion in the prone position. Med Dosim 2015;40:325-32.
   9. Inoue M, Yoshimura M, Sato S, Nakamura M, Yamada M, Hirata K, Sasaki M, Fujimoto T, Ogura M, Hiraoka M. Improvement of registration accuracy in accelerated partial breast irradiation using the point-based rigid-body registration algorithm for patients with implanted fiducial markers. Med Phys 2015;42:1904-10.
   10. Inoue M, Yoshimura M, Kobayashi M, Morinibu A, Itasaka S, Hiraoka M, Harada H. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. Sci Rep 2015;5:15666.
   11. Kishi T, Matsuo Y, Ueki N, Iizuka Y, Nakamura A, Sakanaka K, Mizowaki T, Hiraoka M. Pretreatment modified Glasgow Prognostic Score predicts clinical outcomes after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2015;92:620-7.
   12. Matsuo Y, Verellen D, Poels K, Mukumoto N, Depuydt T, Akimoto M, Nakamura M, Ueki N, Engels B, Collen C, Kokubo M, Hiraoka M, De ridder M. A multi-centre analysis of treatment procedures and error components in dynamic tumour tracking radiotherapy. Radiother Oncol 2015:115:412-8.
   13. Mizowaki T, Aoki M, Nakamura K, Yorozu A, Kokubo M, Karasawa K, Kozuka T, Nakajima N, Sasai K, Akimoto T. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study. J Radiat Res 2015;56:750-6.
   14. Monzen H, Mizowaki T, Yano S, Fujimoto T, Kamomae T, Utsunomiya S, Nakamura M, Hiraoka M. Impact of the Vero4DRT (MHI-TM2000) on the Total Treatment Time in Stereotactic Irradiation. J Nucl Med Radiat Ther 2015;06:1000238(pp1-4).
   15. Monzen H, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, Sonobe M, Nagata Y, Hiraoka M, Date H. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg 2015;99:1122-9.
   16. Nakamura M, Akimoto M, Mukumoto N, Yamada M, Tanabe H, Ueki N, Matsuo Y, Mizowaki T, Kokubo M, Hiraoka M. Influence of the correlation modeling period on the prediction accuracy of infrared marker-based dynamic tumor tracking using a gimbaled X-ray head. Phys Med 2015;31:204-9.
   17. Nakamura M, Takamiya M, Akimoto M, Ueki N, Yamada M, Tanabe H, Mukumoto N, Yokota K, Matsuo Y, Mizowaki T, Kokubo M, Hiraoka M. Target localization errors from fiducial markers implanted around a lung tumor for dynamic tumor tracking. Phys Med 2015;31:934-41.
   18. Nakamura M, Akimoto M, Ono T, Nakamura A, Yano S, Nakata M, Itasaka S, Mizowaki T, Shibuya K, Hiraoka M. Interfraction Positional Variation in Pancreatic Tumors using Daily Breath-hold Cone-beam Computed Tomography with Visual Feedback. J Appl Clin Med Phys. 2015;16:108-16.
   19. Nakayama S, Monzen H, Oonishi Y, Mizote R, Iramina H, Kaneshige S, Mizowaki T. A novel method for dose distribution registration using fiducial marks made by a megavoltage beam in film dosimetry for intensity-modulated radiation therapy quality assurance. Phys Med 2015;31:414-9.
   20. Onimaru R, Shirato H, Shibata T, Hiraoka M, Ishikura S, Karasawa K, Matsuo Y, Kokubo M, Shioyama Y, Matsushita H, Ito Y, Onishi H. Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV<100 cc using a continual reassessment method (JCOG0702). Radiother Oncol 2015;116:276-80.
   21. Sato S, Miyabe Y, Takahashi K, Yamada M, Nakamura M, Ishihara Y, Yokota K, Kaneko S, Mizowaki T, Monzen H, Hiraoka M. Commissioning and quality assurance of Dynamic WaveArc irradiation. J Appl Clin Med Phys 2015;16:73-86.
   22. Shintani T, Masago K, Takayama K, Ueki K, Kimino G, Ueki N, Kosaka Y, Imagumbai T, Katakami N, Kokubo M. Stereotactic Body Radiotherapy for Synchronous Primary Lung Cancer: Clinical Outcome of 18 Cases. Clin Lung Cancer 2015;16:e91-6.
   23. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M, Hiraoka M. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 2015;10:116-25.
   24. Umeda K, Shibata H, Saida S, Hiramatsu H, Arakawa Y, Mizowaki T, Nishiuchi R, Adachi S, Heike T, Watanabe K. Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma. Pediatr Int 2015;57:169-71.
   25. Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 2015;56:561-7.

   2014

   1. Aoki M, Mizowaki T, Akimoto T, Nakamura K, Ejima Y, Jingu K, Tamai Y, Nakajima N, Takemoto S, Kokubo M and Katoh H. Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG. J Radiat Res 2014;55:533-540.
   2. Gaowa A, Horibe T, Kohno M, Sato K, Harada H, Hiraoka M, Tabata Y and Kawakami K. Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo. Journal of controlled release : official journal of the Controlled Release Society 2014;176:1-7.
   3. Iizuka Y, Matsuo Y, Umeoka S, Nakamoto Y, Ueki N, Mizowaki T, Togashi K and Hiraoka M. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET. European journal of radiology 2014;83:2087-2092.
   4. Ikeda I, Mizowaki T, Norihisa Y, Takayama K, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O and Hiraoka M. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study. Jpn J Clin Oncol 2014;44:180-185.
   5. Ikeda I, Mizowaki T, Sawada Y, Nakata M, Norihisa Y, Ogura M and Hiraoka M. Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell. J Radiat Res 2014;55:168-174.
   6. Koubuchi S, Takakura T, Nakamura M, Mizowaki T, Nakata M and Hiraoka M. Accuracy of positional correction for the floor-mounted kV X-ray IGRT system in angled couch positions. Radiol Phys Technol 2014;7:373-378.
   7. Mampuya W A, Matsuo Y, Ueki N, Nakamura M, Mukumoto N, Nakamura A, Iizuka Y, Kishi T, Mizowaki T and Hiraoka M. The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer. J Radiat Res 2014;55:934-939.
   8. Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, Sonobe M, Morita S, Date H and Hiraoka M. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. European journal of cancer 2014: 50(17): 2932-8.
   9. Matsuo Y, Ueki N, Takayama K, Nakamura M, Miyabe Y, Ishihara Y, Mukumoto N, Yano S, Tanabe H, Kaneko S, Mizowaki T, Monzen H, Sawada A, Kokubo M and Hiraoka M. Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac. Radiother Oncol 2014: 112(3): 360-4.
   10. Miki K, Hashimoto H, Inoue T, Matsuoka H, Harada H, Hiraoka M and Ohe K. Sonication-induced formation of size-controlled self-assemblies of amphiphilic Janus-type polymers as optical tumor-imaging agents. Small 2014;10:3119-3130.
   11. Mukumoto N, Nakamura M, Yamada M, Takahashi K, Tanabe H, Yano S, Miyabe Y, Ueki N, Kaneko S, Matsuo Y, Mizowaki T, Sawada A, Kokubo M and Hiraoka M. Intrafractional tracking accuracy in infrared marker-based hybrid dynamic tumour-tracking irradiation with a gimballed linac. Radiother Oncol 2014;111:301-305.
   12. Nakamura A, Itasaka S, Takaori K, Kawaguchi Y, Shibuya K, Yoshimura M, Matsuo Y, Mizowaki T, Uemoto S and M. H. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer : Prolonged disease-free interval associated with favorable prognosis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft … [et al] 2014;190:485-490.
   13. Ogura K, Mizowaki T, Ishida Y and Hiraoka M. Dosimetric advantages of O-ring design radiotherapy system for skull-base tumors. J Appl Clin Med Phys 2014;15:4608.
   14. Sakanaka K, Matsuo Y, Nagata Y, Maki S, Shibuya K, Norihisa Y, Narabayashi M, Ueki N, Mizowaki T and Hiraoka M. Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation. Int J Clin Oncol 2014;19:814-821.
   15. Satoshi Koubuchi T T, Mitsuhiro Nakamura, Takashi Mizowaki, Manabu Nakata, Masahiro Hiraoka. Accuracy of positional correction for the floor-mounted kV X-ray IGRT system in angled couch positions. Radiol Phys Technol 2014;7:373-378.
   16. Shiinoki T, Sawada A, Ishihara Y, Miyabe Y, Matsuo Y, Mizowaki T, Kokubo M and Hiraoka M. Dosimetric impact of gold markers implanted closely to lung tumors: a Monte Carlo simulation. J Appl Clin Med Phys 2014;15:4594.
   17. Watanabe T, Mizowaki T, Arakawa Y, Iizuka Y, Ogura K, Sakanaka K, Miyamoto S and Hiraoka M Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases. Molecular and Clinical Oncology 2014;2:197-202.
   18. Tomohiro Ono Y M, Masahiro Yamada, Takehiro Shiinoki, Akira Sawada, Shuji Kaneko, Hajime Monzen, Takashi Mizowaki, Masaki Kokubo, Masahiro Hiraoka. Geometric and dosimetric accuracy of dynamic tumor-tracking conformal arc irradiation with a gimbaled x-ray head. Medical physics 2014;41:pp1-8.
   19. Tomohiro Ono Y M, Masahiro Yamada, Kenji Yokota, Shuji Kaneko, Akira Sawada, Hajime Monzen, Takashi Mizowaki, Masaki Kokubo, Masahiro Hiraoka. Development of an expanded-field irradiation technique using a gimbaled x-ray head. Medical physics 2014;41:101706(pp101711).
   20. Tsuruta Y, Nakata M, Nakamura M, Matsuo Y, Higashimura K, Monzen H, Mizowaki T and Hiraoka M. Dosimetric comparison of Acuros XB, AAA, and XVMC in stereotactic body radiotherapy for lung cancer. Med Phys 2014;41:081715.
   21. Ueki N, Matsuo Y, Nakamura M, Mukumoto N, Iizuka Y, Miyabe Y, Sawada A, Mizowaki T, Kokubo M and Hiraoka M. Intra- and interfractional variations in geometric arrangement between lung tumours and implanted markers. Radiother Oncol 2014;110:523-528.
   22. Watanabe T, Mizowaki T, Arakawa Y, Iizuka Y, Ogura K, Sakanaka K, Miyamoto S and Hiraoka M. Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases. Mol Clin Oncol 2014;2:197-202.
   23. Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsuo Y, Nomiya T, Nakagawa K and Japanese Radiological Society multi-institutional S s g. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiation oncology 2014;9:112.
   24. Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T, Kanesaka N, Tamamoto T, Asakura H, Kosugi T, Hatano K, Yoshimura M, Yamada K, Tokumaru S, Sekiguchi K, Kobayashi M, Soejima T, Isohashi F, Nemoto K, Nishimura Y and Japanese Radiation Oncology Study G. Factors influencing survival outcome for radiotherapy for biliary tract cancer: A multicenter retrospective study. Radiother Oncol 2014.
   25. Zeng L, Morinibu A, Kobayashi M, Zhu Y, Wang X, Goto Y, Yeom C J, Zhao T, Hirota K, Shinomiya K, Itasaka S, Yoshimura M, Guo G, Hammond E M, Hiraoka M and Harada H. Aberrant IDH3alpha expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis. Oncogene 2014.
   26. Zhao T, Zhu Y, Morinibu A, Kobayashi M, Shinomiya K, Itasaka S, Yoshimura M, Guo G, Hiraoka M and Harada H. HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Scientific reports 2014;4:3793.

   2013

   1. Akimoto M, Nakamura M, Mukumoto N, Tanabe H, Yamada M, Matsuo Y, Monzen H, Mizowaki T, Kokubo M and Hiraoka M. Predictive uncertainty in infrared marker-based dynamic tumor tracking with Vero4DRT. Med Phys 2013;40:091705.
   2. Eriguchi T, Takeda A, Oku Y, Ishikura S, Kimura T, Ozawa S, Nakashima T, Matsuo Y, Nakamura M, Matsumoto Y, Yamazaki S, Sanuki N and Ito Y. Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma — benchmark for a prospective multi-institutional study. Radiation oncology 2013;8:113.
   3. Fujita M, Sasanuma H, Yamamoto K N, Harada H, Kurosawa A, Adachi N, Omura M, Hiraoka M, Takeda S and Hirota K. Interference in DNA replication can cause mitotic chromosomal breakage unassociated with double-strand breaks. PLoS One 2013;8:e60043.
   4. Ikeda I, Mizowaki T, Norihisa Y, Takayama K, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O and Hiraoka M. Long-term Outcomes of Dynamic Conformal Arc Irradiation Combined with Neoadjuvant Hormonal Therapy in Japanese Patients with T1c-T2N0M0 Prostate Cancer: Case Series Study. Jpn J Clin Oncol 2013.
   5. Isobe T, Onn A, Morgensztern D, Jacoby J J, Wu W, Shintani T, Itasaka S, Shibuya K, Koo P J, O’Reilly M S and Herbst R S. Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. J Thorac Oncol 2013;8:140-146.
   6. Ikeda I, Mizowaki T, Sawada Y, Nakata M, Norihisa Y, Ogura M and Hiraoka M. Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell. Journal of Radiation Research 2013.
   7. Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T and Noguchi S. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast cancer research and treatment 2013.
   8. Mami Akimoto M N, Nobutaka Mukumoto, Hiroaki Tanabe, Masahiro Yamada, Yukinori Matsuo, Hajime Monzen, Takashi Mizowaki, Masaki Kokubo, and Masahiro Hiraoka. Predictive uncertainty in infrared marker-based dynamic tumor tracking with Vero4DRT. Medical physics 2013;40:8.
   9. Mampuya W A, Matsuo Y, Nakamura A, Nakamura M, Mukumoto N, Miyabe Y, Narabayashi M, Sakanaka K, Mizowaki T and Hiraoka M. Differences in dose-volumetric data between the analytical anisotropic algorithm and the x-ray voxel Monte Carlo algorithm in stereotactic body radiation therapy for lung cancer. Med Dosim 2013;38:95-99.
   10. Mampuya W A, Nakamura M, Matsuo Y, Ueki N, Iizuka Y, Fujimoto T, Yano S, Monzen H, Mizowaki T and Hiraoka M. Interfraction variation in lung tumor position with abdominal compression during stereotactic body radiotherapy. Med Phys 2013;40:091718.
   11. Matsugi K, Nakamura M, Miyabe Y, Yamauchi C, Matsuo Y, Mizowaki T and Hiraoka M. Evaluation of 4D dose to a moving target with Monte Carlo dose calculation in stereotactic body radiotherapy for lung cancer. Radiol Phys Technol 2013;6:233-240.
   12. Matsuo Y, Onishi H, Nakagawa K, Nakamura M, Ariji T, Kumazaki Y, Shimbo M, Tohyama N, Nishio T, Okumura M, Shirato H and Hiraoka M. Guidelines for respiratory motion management in radiation therapy. J Radiat Res 2013;54:561-568.
   13. Mitsuhiro Nakamura A S, Nobutaka Mukumoto, Kunio Takahashi, Takashi Mizowaki, Masaki Kokubo, Masahiro Hiraoka. Effect of audio instruction on tracking errors using a four-dimensional image-guided radiotherapy system. Journal of applied clinical medical physics / American College of Medical Physics 2013;14:10.
   14. Mizowaki T, Takayama K, Nagano K, Miyabe Y, Matsuo Y, Kaneko S, Kokubo M and Hiraoka M. Feasibility evaluation of a new irradiation technique: three-dimensional unicursal irradiation with the Vero4DRT (MHI-TM2000). Journal of radiation research 2013;54:330-336.
   15. Mukumoto N, Nakamura M, Sawada A, Suzuki Y, Takahashi K, Miyabe Y, Kaneko S, Mizowaki T, Kokubo M and Hiraoka M. Accuracy verification of infrared marker-based dynamic tumor-tracking irradiation using the gimbaled x-ray head of the Vero4DRT (MHI-TM2000). Med Phys 2013;40:041706-041701-041709.
   16. Nakamura A, Shibuya K, Nakamura M, Matsuo Y, Shiinoki T, Nakata M, Mizowaki T and Hiraoka M. Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy. Med Phys 2013;40:021701.
   17. Ogura K, Mizowaki T, Arakawa Y, Ogura M, Sakanaka K, Miyamoto S and Hiraoka M. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiation oncology 2013;8:97.
   18. Ogura K, Mizowaki T, Arakawa Y, Sakanaka K, Miyamoto S and Hiraoka M. Efficacy of salvage stereotactic radiotherapy for recurrent glioma: impact of tumor morphology and method of target delineation on local control. Cancer medicine 2013;2:942-949.
   19. Takakura T, Nakamura M, Shibuya K, Nakata M, Nakamura A, Matsuo Y, Shiinoki T, Higashimura K, Teshima T and Hiraoka M. Effects of interportal error on dose distribution in patients undergoing breath-holding intensity-modulated radiotherapy for pancreatic cancer: evaluation of a new treatment planning method. J Appl Clin Med Phys 2013;14:4252.
   20. Ueki N, Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Norihisa Y, Mizowaki T and Hiraoka M. Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer. J Radiat Res 2013;54:337-343.
   21. Utsunomiya S M H, Mukumoto N, Akimoto M, Mukumoto N, Ishihara Y, Shiinoki T, Nakamra M, Miyabe Y, Sato S, Matsuo S, Hiraoka M. A feasibility study on reduction of the entrance-surface dose to neonates by use of a new digital mobile X-ray system. Radiological physics and technology 2013;6:157-161.
   22. Mampuya W A, Matsuo Y, Ueki N, Iizuka Y, Fujimoto T, Yano S, Monzen H, Mizowaki T, and Hiraoka M. Interfraction variation in lung tumor position with abdominal compression during stereotactic body radiotherapy. Medical physics 2013;40:7.
   23. Watanabe T, Monzen H, Hara M, Mizowaki T and Hiraoka M. Pharmacokinetic model of myocardial (99m)Tc-sestamibi washout. Ann Nucl Med 2013;27:279-284.
   24. Zhu Y, Zhao T, Itasaka S, Zeng L, Yeom C J, Hirota K, Suzuki K, Morinibu A, Shinomiya K, Ou G, Yoshimura M, Hiraoka M and Harada H. Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells. Oncogene 2013;32:2058-2068.

   2012

   1. Akimoto M, Nakamura M, Mukumoto N, Yamada M, Ueki N, Matsuo Y, Sawada A, Mizowaki T, Kokubo M Hiraoka M. Optimization of the x-ray monitoring angle for creating a correlation model between internal and external respiratory signals. Med Phys 2012;39:6309-6315.
   2. Chen F, Okubo K, Sonobe M, Shibuya K, Matsuo Y, Kim YH, Yanagihara K, Bando T Date H. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage iiia-n2 lung cancer. World journal of surgery 2012;36:2858-2864.
   3. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ Hiraoka M. Cancer cells that survive radiation therapy acquire hif-1 activity and translocate towards tumour blood vessels. Nature communications 2012;3:783.
   4. Kai S, Tanaka T, Daijo H, Harada H, Kishimoto S, Suzuki K, Takabuchi S, Takenaga K, Fukuda K Hirota K. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. Antioxid Redox Signal 2012;16:203-216.
   5. Li Z, Kawamura K, Kawashita M, Kudo TA, Kanetaka H Hiraoka M. In vitro assessment of poly(methylmethacrylate)-based bone cement containing magnetite nanoparticles for hyperthermia treatment of bone tumor. J Biomed Mater Res A 2012;100:2537-2545.
   6. Matsuo Y, Shibuya K, Nagata Y, Norihisa Y, Narabayashi M, Sakanaka K, Ueki N, Mizowaki T Hiraoka M. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol 2012;7:453-456.
   7. Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y Hiraoka M. Dose–volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012;83:e545-549.
   8. Miki K NK, Matsuoka H, Yeom CJ, Harada H, Hiraoka M, Ohe K. Amphiphilic brush-like copolymers involving hydrophobic amino acid- and oligopeptide-side chains for optical tumor imaging in vivo. Bull Chem Soc. 2012;85:1277-1286.
   9. Mizowaki T, Hatano K Hiraoka M. Surveillance on interfacility differences in dose-prescription policy of intensity-modulated radiation therapy plans for prostate cancer. Journal of radiation research 2012;53:608-614.
   10. Mizowaki T, Takayama K, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O Hiraoka M. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for japanese patients with t1c-t2n0m0 prostate cancer. International journal of clinical oncology 2012;17:562-568.
   11. Mukumoto N, Nakamura M, Sawada A, Takahashi K, Miyabe Y, Takayama K, Mizowaki T, Kokubo M Hiraoka M. Positional accuracy of novel x-ray-image-based dynamic tumor-tracking irradiation using a gimbaled mv x-ray head of a vero4drt (mhi-tm2000). Med Phys 2012;39:6287-6296.
   12. Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T Hiraoka M. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;84:369-375.
   13. Nakamura K, Akimoto T, Mizowaki T, Hatano K, Kodaira T, Nakamura N, Kozuka T, Shikama N Kagami Y. Patterns of practice in intensity-modulated radiation therapy and image-guided radiation therapy for prostate cancer in japan. Japanese journal of clinical oncology 2012;42:53-57.
   14. Nakamura M, Kishimoto S, Iwamura K, Shiinoki T, Nakamura A, Matsuo Y, Shibuya K Hiraoka M. Dosimetric investigation of breath-hold intensity-modulated radiotherapy for pancreatic cancer. Med Phys 2012;39:48-54.
   15. Nakamura M, Miyabe Y, Matsuo Y, Kamomae T, Nakata M, Yano S, Sawada A, Mizowaki T Hiraoka M. Experimental validation of heterogeneity-corrected dose-volume prescription on respiratory-averaged ct images in stereotactic body radiotherapy for moving tumors. Med Dosim 2012;37:20-25.
   16. Nakamura M, Shibuya K, Nakamura A, Shiinoki T, Matsuo Y, Nakata M, Sawada A, Mizowaki T Hiraoka M. Interfractional dose variations in intensity-modulated radiotherapy with breath-hold for pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;82:1619-1626.
   17. Narabayashi M, Mizowaki T, Matsuo Y, Nakamura M, Takayama K, Norihisa Y, Sakanaka K Hiraoka M. Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors. J Radiat Res 2012;53:777-784.
   18. Nishimura Y, Koike R, Ogawa K, Sasamoto R, Murakami Y, Itoh Y, Negoro Y, Itasaka S, Sakayauchi T Tamamoto T. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: The japanese radiation oncology study group (jrosg) survey. Int J Clin Oncol 2012;17:48-54.
   19. Norihisa Y, Mizowaki T, Takayama K, Miyabe Y, Matsugi K, Matsuo Y, Narabayashi M, Sakanaka K, Nakamura A, Nagata Y Hiraoka M. Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage c prostate cancer based on a planning protocol. Int J Clin Oncol 2012;17:505-511.
   20. Nozaki M, Kagami Y, Mitsumori M Hiraoka M. A multicenter investigation of late adverse events in japanese women treated with breast-conserving surgery plus conventional fractionated whole-breast radiation therapy. Jpn J Clin Oncol 2012.
   21. Ogura K, Mizowaki T, Ogura M, Sakanaka K, Arakawa Y, Miyamoto S Hiraoka M. Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol 2012;109:425-432.
   22. Saji S, Hiraoka M, Tokuda Y, Fukui N Ikeda T. Trends in local therapy application for early breast cancer patients in the japanese breast cancer society breast cancer registry during 2004-2009. Breast Cancer 2012;19:1-3.
   23. Sakanaka K, Mizowaki T Hiraoka M. Dosimetric advantage of intensity-modulated radiotherapy for whole ventricles in the treatment of localized intracranial germinoma. Int J Radiat Oncol Biol Phys 2012;82:e273-280.
   24. Yeom CJ, Goto Y, Zhu Y, Hiraoka M Harada H. Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors. International journal of molecular sciences 2012;13:13949-13965.
   25. Youshi Fujita, Takahiro Kuchimaru, Tetsuya Kadonosono, Shotaro Tanaka, Yoshiki Hase, Hidekazu Tomimoto, Masahiro Hiraoka, Shinae Kizaka-Kondoh, Masafumi Ihara Takahashi R. In vivo imaging of brain ischemia using an oxygen-dependent degradative fusion protein probe. PLOS ONE 2012.

   2011

   1. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, Togashi K, Itasaka S, Hiraoka M, Misaki T, Konishi J: Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med2011, 52(5):683-689. PMID:21498534
   2. Hiraoka M:[Current situation and perspectives of radiation oncology].Nihon Rinsho2011, 69 Suppl 5:404-407. PMID:22208011
   3. Ishikura S, Ito Y, Hiraoka M: JCOG Radiation Therapy Study Group: History and Achievements. Jpn J Clin Oncol 2011. PMID:21980050
   4. Li Z, Kawashita M, Araki N, Mitsumori M, Hiraoka M, Doi M:Preparation of magnetic iron oxide nanoparticles for hyperthermia of cancer in a FeCl?-NaNO?-NaOH aqueous system. J Biomater Appl 2011, 25(7):643-661. PMID:20207773
   5. Matsuo Y, Shibuya K, Nagata Y, Norihisa Y, Narabayashi M, Sakanaka K, Ueki N, Mizowaki T, Hiraoka M: Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol2012, 7(2):453-456. PMID:22252562
   6. Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T, Narabayashi M, Sakanaka K, Hiraoka M: Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1104-1111. PMID:20472343
   7. Miki K, Kimura A, Oride K, Kuramochi Y, Matsuoka H, Harada H, Hiraoka M, Ohe K: High-Contrast Fluorescence Imaging of Tumors In Vivo Using Nanoparticles of Amphiphilic Brush-Like Copolymers Produced by ROMP.Angew Chem Int Ed Engl 2011. PMID:21656616
   8. Miyabe Y, Sawada A, Takayama K, Kaneko S, Mizowaki T, Kokubo M, Hiraoka M: Positioning accuracy of a new image-guided radiotherapy system. Med Phys 2011, 38(5):2535-2541. PMID:21776788
   9. Mizowaki T, Takayama K, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O, Hiraoka M: Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.Int J Clin Oncol2011. PMID:21968911
   10. Nakajima A, Nishiyama K, Morimoto M, Nakamura S, Suzuki O, Kawaguchi Y, Miyagi K, Fujii T, Yoshino K:Definitive Radiotherapy for T1-2 Hypopharyngeal Cancer: A Single-Institution Experience.Int J Radiat Oncol Biol Phys 2011. PMID:21640496
   11. Nakamura M, Kishimoto S, Iwamura K, Shiinoki T, Nakamura A, Matsuo Y, Shibuya K, Hiraoka M:Dosimetric investigation of breath-hold intensity-modulated radiotherapy for pancreatic cancer. Med Phys 2012, 39(1):48. PMID:22225274
   12. Nakamura M, Miyabe Y, Matsuo Y, Kamomae T, Nakata M, Yano S, Sawada A, Mizowaki T, Hiraoka M: Experimental validation of heterogeneity-corrected dose-volume prescription on respiratory-averaged CT images in stereotactic body radiotherapy for moving tumors.Med Dosim2011. PMID:21497502
   13. Nakamura M, Shibuya K, Nakamura A, Shiinoki T, Matsuo Y, Nakata M, Sawada A, Mizowaki T, Hiraoka M: Interfractional Dose Variations in Intensity-Modulated Radiotherapy With Breath-Hold for Pancreatic Cancer.Int J Radiat Oncol Biol Phys2011. PMID:21477941
   14. Nakamura M, Shibuya K, Shiinoki T, Matsuo Y, Nakamura A, Nakata M, Sawada A, Mizowaki T, Hiraoka M: Positional reproducibility of pancreatic tumors under end-exhalation breath-hold conditions using a visual feedback technique. Int J Radiat Oncol Biol Phys 2011, 79(5):1565-1571. PMID:20832187
   15. Norihisa Y, Mizowaki T, Takayama K, Miyabe Y, Matsugi K, Matsuo Y, Narabayashi M, Sakanaka K, Nakamura A, Nagata Y, Hiraoka M: Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol.Int J Clin Oncol2011. PMID:21960356
   16. Numasaki H, Shibuya H, Nishio M, Ikeda H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Ando Y, Tsukamoto N, Terahara A, Nakamura K, Mitsumori M, Nishimura T, Hareyama M, Teshima T, Committee JSoTRaOD: National Medical Care System May Impede Fostering of True Specialization of Radiation Oncologists: Study Based on Structure Survey in Japan.Int J Radiat Oncol Biol Phys 2011. PMID:21470792
   17. Numasaki H, Shibuya H, Nishio M, Ikeda H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Ando Y, Tsukamoto N, Terahara A, Nakamura K, Mitsumori M, Nishimura T, Hareyama M, Teshima T, Committee JSTROD: Japanese structure survey of radiation oncology in 2007 with special reference to designated cancer care hospitals.Strahlenther Onkol 2011, 187(3):167-174. PMID:21347636
   18. Saha D, Dunn H, Zhou H, Harada H, Hiraoka M, Mason RP, Zhao D: In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model. J Vis Exp2011(56). PMID:21989061
   19. Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T: Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004-2009. Breast Cancer2012, 19(1):1-3. PMID:22124993
   20. Sakanaka K, Mizowaki T, Arakawa Y, Araki N, Oya N, Takahashi JA, Mikuni N, Miyamoto S, Hashimoto N, Hiraoka M: Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience. Int J Clin Oncol 2011, 16(1):27-32. PMID:20830603
   21. Sakanaka K, Mizowaki T, Hiraoka M:Dosimetric Advantage of Intensity-modulated Radiotherapy for Whole Ventricles in the Treatment of Localized Intracranial Germinoma. Int J Radiat Oncol Biol Phys2011. PMID:21640515
   22. Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y, Mitsumori M, Hiraoka M: Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 2011, 34(2):115-119. PMID:20065850
   23. Shiinoki T, Shibuya K, Nakamura M, Nakamura A, Matsuo Y, Nakata M, Sawada A, Mizowaki T, Itoh A, Hiraoka M: Interfractional Reproducibility in Pancreatic Position Based on Four-Dimensional Computed Tomography. Int J Radiat Oncol Biol Phys2011. PMID:21493016
   24. Takayama K, Mizowaki T, Negoro Y, Norihisa Y, Hiraoka M: Impact of double-balloon rectal catheter use in external-beam radiotherapy for prostate cancer. Int J Clin Oncol2011, 16(1):50-56. PMID:20922449
   25. Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS: Identifying gaps in the locoregional management of early breast cancer: highlights from the kyoto consensus conference. Ann Surg Oncol 2011, 18(10):2885-2892. PMID:21431404
   26. Toita T, Kato S, Niibe Y, Ohno T, Kazumoto T, Kodaira T, Kataoka M, Shikama N, Kenjo M, Tokumaru S, Yamauchi C, Suzuki O, Sakurai H, Numasaki H, Teshima T, Oguchi M, Kagami Y, Nakano T, Hiraoka M, Mitsuhashi N:Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys 2011. PMID:21470794
   27. Toita T, Ohno T, Kaneyasu Y, Kato T, Uno T, Hatano K, Norihisa Y, Kasamatsu T, Kodaira T, Yoshimura R, Ishikura S, Hiraoka M, Group ftJRTS: A Consensus-based Guideline Defining Clinical Target Volume for Primary Disease in External Beam Radiotherapy for Intact Uterine Cervical Cancer.Jpn J Clin Oncol 2011, 41(9):1119-1126. PMID:21875938
   28. Tomita N, Toita T, Kodaira T, Shinoda A, Uno T, Numasaki H, Teshima T, Mitsumori M: Changing trend in the patterns of pretreatment diagnostic assessment for patients with cervical cancer in Japan. Gynecol Oncol 2011. PMID:21945554
   29. Ueda M, Kudo T, Mutou Y, Umeda IO, Miyano A, Ogawa K, Ono M, Fujii H, Kizaka-Kondoh S, Hiraoka M, Saji H: Evaluation of [(125) I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: Comparison among SPECT/CT imaging, autoradiography, and immunohistochemistry. Cancer Sci 2011. PMID:21824221

   2010

   1. ABE, E., MIZOWAKI, T., NORIHISA, Y., NARITA, Y., MATSUO, Y., NARABAYASHI, M., NAGATA, Y. & HIRAOKA, M. Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer. J Appl Clin Med Phys, 11, 3193, 2010.
   2. CHEN, F., MATSUO, Y., YOSHIZAWA, A., SATO, T., SAKAI, H., BANDO, T., OKUBO, K., SHIBUYA, K. & DATE, H. Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients. J Thorac Oncol, 5, 1999-2002, 2010.
   3. FUJITA, Y., IHARA, M., USHIKI, T., HIRAI, H., KIZAKA-KONDOH, S., HIRAOKA, M., ITO, H. & TAKAHASHI, R. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke, 41, 2938-43, 2010.
   4. HARADA, H. & HIRAOKA, M. 2010. Hypoxia-Inducible Factor 1 in Tumor Radioresistance. Current Signal Transduction Therapy, 5, 188-196. HIRAOKA, M., MATSUO, Y. & TAKAYAMA, K. Stereotactic body radiation therapy for lung cancer: achievements and perspectives. Jpn J Clin Oncol, 40, 846-54, 2010.
   5. KOMATSU, H., HARDA, H., TANABE, K., HIRAOKA, M. & NISHIMOTO, S.-I. Indolequinone-rhdol Conjugate as a fluorescent probe for hypoxic cells:enzymatic activation and fluorescence properties. Med Chem Comm, 1, 50-53, 2010.
   6. KUDO, T., UEDA, M., KONISHI, H., KAWASHIMA, H., KUGE, Y., MUKAI, T., MIYANO, A., TANAKA, S., KIZAKA-KONDOH, S., HIRAOKA, M. & SAJI, H. PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel (18)F-Labeled Biotin Derivative. Mol Imaging Biol. 2010
   7. LI, Z., KAWASHITA, M., ARAKI, N., MITSUMORI, M., HIRAOKA, M., and DOI, M. Magnetic SiO 2 gel microspheres for arterial embolization hyperthermia. Biomedical Materials, 5, 065010, 2010.
   8. LI, Z., KAWASHITA, M., ARAKI, N., MITSUMORI, M., HIRAOKA, M. & DOI, M. Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer. Materials Science and Engineering: C, 30, 990-996, 2010.
   9. MATSUO, Y., NAKAMOTO, Y., NAGATA, Y., SHIBUYA, K., TAKAYAMA, K., NORIHISA, Y., NARABAYASHI, M., MIZOWAKI, T., SAGA, T., HIGASHI, T., TOGASHI, K. & HIRAOKA, M. 2010a. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol, 97, 200-4. , 2010
   10. MIKI, K., ORIDE, K., INOUE, S., KURAMOCHI, Y., NAYAK, R., MATSUOKA, H., HARADA, H., HIRAOKA, M. & OHE, K. Ring-opening metathesis polymerization-based synthesis of polymeric nanoparticles for enhanced tumor imaging in vivo: Synergistic effect of folate-receptor targeting and PEGylation. Biomaterials, 31, 934-42, 2010.
   11. MIYAZAKI, T., KAI, T., ISHIDA, E., KAWASHITA, M. & HIRAOKA, M. Fabrication of yttria microcapsules for radiotherapy from water/oil emulsion. Journal of the Ceramic Society of Japan, 118, 479-482, 2010.
   12. NAKAMURA, M., SAWADA, A., ISHIHARA, Y., TAKAYAMA, K., MIZOWAKI, T., KANEKO, S., YAMASHITA, M., TANABE, H., KOKUBO, M. & HIRAOKA, M. Dosimetric characterization of a multileaf collimator for a new four-dimensional image-guided radiotherapy system with a gimbaled x-ray head, MHI-TM2000. Medical Physics, 37, 4684-4691, 2010.
   13. NAKAMURA, M., SHIBUYA, K., SHIINOKI, T., MATSUO, Y., NAKAMURA, A., NAKATA, M., SAWADA, A., MIZOWAKI, T. & HIRAOKA, M. Positional Reproducibility of Pancreatic Tumors Under End-Exhalation Breath-Hold Conditions Using a Visual Feedback Technique. Int J Radiat Oncol Biol Phys, 79, 1565-1571, 2010.
   14. OGAWA, K., ITO, Y., KARASAWA, K., OGAWA, Y., ONISHI, H., KAZUMOTO, T., SHIBUYA, K., SHIBUYA, H., OKUNO, Y., NISHINO, S., OGO, E., UCHIDA, N., NEMOTO, K., NISHIMURA, Y. & CANCERS, J. W. S. O. G. Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey. Int J Radiat Oncol Biol Phys, 77, 743-50, 2010.
   15. SAKAMOTO, M., MIZOWAKI, T., MITSUMORI, M., TAKAYAMA, K., SASAI, K., NORIHISA, Y., KAMOTO, T., NAKAMURA, E., OGAWA, O. & HIRAOKA, M. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer. Int J Clin Oncol, 15, 571-577, 2010.
   16. SAKANAKA, K., MIZOWAKI, T., ARAKAWA, Y., ARAKI, N., OYA, N., TAKAHASHI, J., MIKUNI, N., MIYAMOTO, S., HASHIMOTO, N. & HIRAOKA, M. Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience. Int J Clin Oncol, 16, 27-32, 2010.
   17. TAKAKURA, T., MIZOWAKI, T., NAKATA, M., YANO, S., FUJIMOTO, T., MIYABE, Y., NAKAMURA, M. & HIRAOKA, M. The geometric accuracy of frameless stereotactic radiosurgery using a 6D robotic couch system. Phys Med Biol, 55, 1-10, 2010.
   18. TAKAYAMA, K., MIZOWAKI, T., NEGORO, Y., NORIHISA, Y. & HIRAOKA, M. Impact of double-balloon rectal catheter use in external-beam radiotherapy for prostate cancer. Int J Clin Oncol, 16, 50-56, 2010.
   19. TOITA, T., OHNO, T., KANEYASU, Y., UNO, T., YOSHIMURA, R., KODAIRA, T., FURUTANI, K., KASUYA, G., ISHIKURA, S., KAMURA, T., HIRAOKA, M. & GROUP, J. C. O. A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol, 40, 456-63, 2010.
   20. UEDA, M., KUDO, T., KUGE, Y., MUKAI, T., TANAKA, S., KONISHI, H., MIYANO, A., ONO, M., KIZAKA-KONDOH, S., HIRAOKA, M. & SAJI, H. Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha. Eur J Nucl Med Mol Imaging, 37, 1566-74, 2010.
   21. USHIKI, T., KIZAKA-KONDOH, S., ASHIHARA, E., TANAKA, S., MASUKO, M., HIRAI, H., KIMURA, S., AIZAWA, Y., MAEKAWA, T. & HIRAOKA, M. Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation. PLoS One, 5, e11114, 2010.
   22. ZHAO, T., HARADA, H., TERAMURA, Y., TANAKA, S., ITASAKA, S., MORINIBU, A., SHINOMIYA, K., ZHU, Y., HANAOKA, H., IWATA, H., SAJI, H. & HIRAOKA, M. A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells. J Control Release, 144, 109-14, 2010.
   23. 溝脇 尚志, 高山 賢二. 前立腺がんに対する強度変調放射線治療（IMRT）の現状と課題. Rad Fan, 8(12), 49-51, 2010.
   24. 溝脇 尚志, 高山 賢二, 則久 佳毅, 矢野 慎輔, 神波 大己, 井上 貴博, 清水 洋祐, 小川 修, 平岡 眞寛. C期前立腺癌に対する放射線外部照射療法の至適治療ストラテジー：ネオジュバント内分泌療法併用高線量局所外部照射の治療成績. 泌尿器外科, 23（8）, 1049-1051, 2010.
   25. 澁谷 景子, 平岡 眞寛. 切除不能膵癌に対する集学的治療－切除不能膵癌に対する放射線治療. 消化器外科, 33(12), 1853-1860, 2010.
   26. 門之園哲哉, 口丸高弘, 近藤科江, 平岡眞寛 すい臓がんの進行とプロドラッグ治療効果の光イメージング. JSMI Report, 3, 19-21, 2010.

   2009

   1. Harada H, Itasaka S, Kizaka-Kondoh S, et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. Feb 2009;284(8):5332-5342.

   2. Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer. Mar 2009;100(5):747-757.

   3. Hirata N, Fujisawa Y, Tanabe K, Harada H, Hiraoka M, Nishimoto S. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Org Biomol Chem. Feb 2009;7(4):651-654.

   4. Kizaka-Kondoh S, Itasaka S, Zeng L, et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res. May 2009;15(10):3433-3441.

   5. Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev. Jul 2009;61(7-8):623-632.

   6. Kudo T, Ueda M, Kuge Y, et al. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med. Jun 2009;50(6):942-949.

   7. Makino A, Kizaka-Kondoh S, Yamahara R, et al. Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials. Oct 2009;30(28):5156-5160.

   8. Matsugi K, Narita Y, Sawada A, et al. Measurement of interfraction variations in position and size of target volumes in stereotactic body radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):543-548.

   9. Miki K, Kuramochi Y, Oride K, et al. Ring-opening metathesis polymerization-based synthesis of ICG-containing amphiphilic triblock copolymers for in vivo tumor imaging. Bioconjug Chem. Mar 2009;20(3):511-517.

   10. Mitsumori M, Hiraoka M, Inaji H, et al. Impact of radiation therapy on breast-conserving therapy for breast cancer in Japanese women: a retrospective analyses of multi-institutional experience. Kansai Breast Cancer Radiation Therapy Study Group. Oncol Rep. Jun 2009;21(6):1461-1466.

   11. Miyabe Y, Narita Y, Mizowaki T, et al. New algorithm to simulate organ movement and deformation for four-dimensional dose calculation based on a three-dimensional CT and fluoroscopy of the thorax. Med Phys. Oct 2009;36(10):4328-4339.

   12. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):343-347.

   13. Nakamura M, Narita Y, Matsuo Y, et al. Effect of audio coaching on correlation of abdominal displacement with lung tumor motion. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):558-563.

   14. Nakamura M, Narita Y, Sawada A, et al. Impact of motion velocity on four-dimensional target volumes: a phantom study. Med Phys. May 2009;36(5):1610-1617.

   15. Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol. Aug 2009;92(2):260-265.

   16. Okubo K, Sonobe M, Fujinaga T, et al. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. Nov 2009;57(11):585-590.

   17. Ou G, Itasaka S, Zeng L, et al. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):463-467.

   18. Sakamoto T, Oya N, Shibuya K, Nagata Y, Hiraoka M. Dose-response relationship and dose optimization in radiotherapy of postoperative keloids. Radiother Oncol. May 2009;91(2):271-276.

   19. Takayama K, Mizowaki T, Kokubo M, et al. Initial validations for pursuing irradiation using a gimbals tracking system. Radiother Oncol. Oct 2009;93(1):45-49.

   20. Tanabe K, Harada H, Narazaki M, et al. Monitoring of biological one-electron reduction by (19)F NMR using hypoxia selective activation of an (19)F-labeled indolequinone derivative. J Am Chem Soc. Nov 2009;131(44):15982-15983.

   2008

   1. Harada H, Xie X, Itasaka S, Zeng L, Zhu Y, Morinibu A, Shinomiya K, Hiraoka M. Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. Biochem Biophys Res Commun, 373: 533-538, 2008. PMID: 18586004
   2. Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, Hareyama M, Sugita T, Mitsuhashi N, Yamashita T, Aoki M, Sai H, Hirokawa Y, Sakata K, Karasawa K, Tomida A, Tsuruo T, Miki Y, Noda T, Hiraoka M. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res, 14: 6683-6689, 2008. PMID: 18927311
   3. Kawashita M, Domi S, Saito Y, Aoki M, Ebisawa Y, Kokubo T, Saito T, Takano M, Araki N, Hiraoka M. In vitro heat generation by ferrimagnetic maghemite microspheres for hyperthermic treatment of cancer under an alternating magnetic field. J Mater Sci Mater Med, 19: 1897-1903, 2008. PMID: 17914614
   4. Kosaka Y, Mitsumori M, Yamauchi C, Narita Y, Hiraoka M. Feasibility of accelerated partial breast irradiation using three-dimensional conformal radiation therapy for Japanese women: a theoretical plan using six patients’ CT data. Breast Cancer, 15: 108-114, 2008. PMID: 18224404
   5. Mitsumori M, Hiraoka M. Current status of accelerated partial breast irradiation. Breast Cancer, 15: 101-107, 2008. PMID: 18224403
   6. Naka K, Narita A, Tanaka H, Chujo Y, Morita M, Inubushi T, Nishimura I, Hiruta J, Shibayama H, Koga M, Ishibashi S, Seki J, Kizaka-Kondoh S, Hiraoka M. Biomedical applications of imidazolium cation-modified iron oxide nanoparticles Polym Adv Technol, 19: 1421-1429, 2008.
   7. Nakamura K, Kodaira T, Shikama N, Kagami Y, Ishikura S, Shibata T, Hiraoka M. Accelerated fractionation versus conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study: Japan Clinical Oncology Group study (JCOG 0701). Jpn J Clin Oncol, 38: 387-389, 2008. PMID: 18390558
   8. Nakamura M, Narita Y, Matsuo Y, Narabayashi M, Nakata M, Yano S, Miyabe Y, Matsugi K, Sawada A, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M. Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Med Phys, 35: 4142-4148, 2008. PMID: 18841867
   9. Nakayama H, Mizowaki T, Narita Y, Kawada N, Takahashi K, Mihara K, Hiraoka M. Development of a three-dimensionally movable phantom system for dosimetric verifications. Med Phys, 35: 1643-1650, 2008. PMID: 18561639
   10. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys, 72: 398-403, 2008. PMID: 18374506
   11. Tanabe K, Hirata N, Harada H, Hiraoka M, Nishimoto S. Emission under hypoxia: one-electron reduction and fluorescence characteristics of an indolequinone-coumarin conjugate. Chembiochem, 9: 426-432, 2008. PMID: 18224643
   12. Tanisaka H, Kizaka-Kondoh S, Makino A, Tanaka S, Hiraoka M, Kimura S. Near-infrared fluorescent labeled peptosome for application to cancer imaging. Bioconjug Chem, 19: 109-117, 2008. PMID: 18163535
   13. Yamada K, Akiyama N, Yamada S, Tanaka H, Saito S, Hiraoka M, Kizaka-Kondoh S. Taip2 is a novel cell death-related gene expressed in the brain during development. Biochem Biophys Res Commun, 369: 426-431, 2008. PMID: 18291095
   14. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, Kizaka-Kondoh S, Morinibu A, Shinomiya K, Hiraoka M. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci, 99: 2327-2335, 2008. PMID: 18823375
   15. Zhu SY, Mizowaki T, Norihisa Y, Takayama K, Nagata Y, Hiraoka M. Comparisons of the impact of systematic uncertainties in patient setup and prostate motion on doses to the target among different plans for definitive external-beam radiotherapy for prostate cancer. Int J Clin Oncol, 13: 54-61, 2008. PMID: 18307020

   2007

   1		Lyshchik A., Higashi T., Asato R., Tanaka S., Ito J., Hiraoka M., Insana M. F., Brill A. B., Saga T., Togashi K.: Cervical Lymph Node Metastases: Diagnosis at Sonoelastography–Initial Experience., Radiology, 247(1):258-67, 2007
   2		Matsuo Y., Takayama K., Nagata Y., Kunieda E., Tateoka K., Ishizuka N., Mizowaki T., Norihisa Y., Sakamoto M., Narita Y., Ishikura S., Hiraoka M.: Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys, 68(2):416-25, 2007
   3		Kano H., Takahashi J. A., Katsuki T., Araki N., Oya N., Hiraoka M., Hashimoto N.: Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol, 84(1): 41-47, 2007.
   4		Yamamoto T., Mizowaki T., Miyabe Y., Takegawa H., Narita Y., Yano S., Nagata Y., Teshima T., Hiraoka M.: An integrated Monte Carlo dosimetric verification system for radiotherapy treatment planning. Phys Med Biol, 52(7): 1991-2008, 2007
   5		Nagata Y., Matsuo Y., Takayama K., Norihisa Y., Mizowaki T., Mitsumori M., Shibuya K., Yano S., Narita Y., Hiraoka M.: Current status of stereotactic body radiotherapy for lung cancer., Int J Clin Oncol., 12(1): 3-7, 2007
   6		Hiraoka M., Matsuo Y., Nagata Y.: Stereotactic body radiation therapy (SBRT) for early-stage lung cancer, Cancer Radiother, 11(1-2): 32-5, 2007
   7		Zeng L., Kizaka-Kondoh S., Itasaka S., Xie X., Inoue M., Tanimoto K., Shibuya K., Hiraoka M: Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions., Cancer Sci., 98(9): 1394-401, 2007
   8		Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T.: Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer., Cancer Res, 67(9): 4157-63, 2007
   9		Liu J., Harada H., Ogura M., Shibata T., Hiraoka, M.: Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts., Br J Cancer, 96(12): 1871-1878, 2007
   10		Kamino Y., Miura S., Kokubo M., Yamashita I., Hirai E., Hiraoka M., Ishikawa J.: Development of an ultrasmall C-band linear accelerator guide for a four-dimensional image-guided radiotherapy system with a gimbaled x-ray head., Med Phys., 34(5): 1797-1808, 2007
   11		Mitsumori M., Zhi-Fan Z., Oliynychenko P., Park J. H., Choi I. B., Tatsuzaki H., Tanaka Y., Hiraoka M.: Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency., Int J Clin Oncol., 12(3): 192-98, 2007
   12		Matsui K., Nagata Y., Hiraoka M. : Radiotherapy for Erdheim-Chester disease., Int J Clin Oncol., 12(3): 238-241, 2007.
   13		Harada, H., Kizaka-Kondoh, S., Li, G., Itasaka, S., Shibuya, K., Inoue, M., and Hiraoka, M. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene, 26: 7508-7516, 2007.
   14		Harada H., Kizaka-Kondoh S., Itasaka S., Shibuya K., Morinibu A., Shinomiya K., Hiraoka M.: The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts., Biochem Biophys Res Commun, 360(4):791-6, 2007
   15		Onishi H., Shirato H., Nagata Y., Hiraoka M., Fujino M., Gomi K., Niibe Y., Karasawa K., Hayakawa K., Takai Y., Kimura T., Takeda A., Ouchi A., Hareyama M., Kokubo M., Hara R., Itami J., Yamada K., Araki T.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study., J Thorac Oncol, 2(7 Suppl 3): S94-100, 2007
   16		Hiraoka M., Ishikura S.: A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer., J Thorac Oncol., 2(7 Suppl 3): S115-117, 2007
   17		Yoshimura K., Kamoto T., Nakamura E., Segawa T., Kamba T., Takahashi T., Nishiyama H., Ito N., Takayama K., Mizowaki T., Mitsumori M., Hiraoka M., Ogawa O.: Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy., Prostate Cancer Prostatic Dis., 10(3): 288-92, 2007
   18		Kamino Y., Tsukuda K., Kokubo M., Miura S., Hirai E., Hiraoka M., Ishikawa, J.: Development of a new concept automatic frequency controller for an ultrasmall C-band linear accelerator guide. Med Phys, 34(8): 3243-3248, 2007.
   19		Yamauchi C., Mitsumori M., Sai H., Imagunbai T., Negoro Y., Sasaki Y., Hiraoka M., Shikama N., Sasaki S., Takegawa H., Inoue T., Teshima T.: Patterns of Care Study of Breast-conserving Therapy in Japan: Comparison of the Treatment Process between 1995-1997 and 1999-2001 Surveys., Jpn J Clin Oncol., 37(10):737-43, 2007
   20		Matsuo Y., Nagata Y., Mizowaki T., Takayama K., Sakamoto T., Sakamoto M., Norihisa Y., Hiraoka M.: Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol 2007. 12(5): p. 356-62.
   21		Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jurgensmeier JM, Milas L, Ang K, Herbst RS, O’Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1534-43.
   22		Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O’Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007 Feb;6(2):471-83.
   23		Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O’Reilly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8.

   2006

   1		Fujino M., Shirato H., Onishi H., Kawamura H., Takayama K., Koto M., Onimaru R., Nagata Y., Hiraoka M.: Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors., Cancer J., 12(1): 41-6, 2006
   2		Harada H., Kizaka-Kondoh S., Hiraoka M.: Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment., Breast Cancer, 13(1): 16-26,2006
   3		Kageyama Y., Sugiyama H., Ayame H., Iwai A., Fujii Y., Huang L. E., Kizaka-Kondoh S., Hiraoka M., Kihara K.: Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element., Acta Oncol., 45(3): 317-24, 2006
   4		Kawashita M., Sadaoka K., Kokubo T., Saito T., Takano M., Araki N., Hiraoka M.: Enzymatic preparation of hollow magnetite microspheres for hyperthermic treatment of cancer., J Mater Sci Mater Med., 17(7): 605-10, 2006
   5		Kubo T., Shibata T., Itoh K., Maetani Y., Isoda H., Hiraoka M., Egawa H., Tanaka K., Togashi K.: Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation., Radiology, 239(1): 285-90, 2006
   6		Okada T., Miki Y., Fushimi Y., Hanakawa T., Kanagaki M., Yamamoto A., Urayama S., Fukuyama H., Hiraoka M., Togashi K.: Diffusion-tensor fiber tractography: intraindividual comparison of 3.0-T and 1.5-T MR imaging., Radiology, 238(2): 668-78, 2006
   7		Oya N., Sasai K., Tachiiri S., Sakamoto T., Nagata Y., Okada T., Yano S., Ishikawa T., Uchiyama T., Hiraoka M.: Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis., Int J Hematol., 83(1): 86-91, 2006
   8		Oya N., Shibuya K., Sakamoto T., Mizowaki T., Doi R., Fujimoto K., Imamura M., Nagata Y., Hiraoka M.: Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine., Pancreatology, 6(1-2): 109-16, 2006
   9		Sakamoto M., Oya N., Mizowaki T., Araki N., Nagata Y., Takayama K., Takahashi J. A., Kano H., Katsuki T., Hashimioto N., Hiraoka M.: Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas., J Neurooncol., 77(1): 53-8, 2006
   10		Shibata T., Shibata T., Maetani Y., Isoda H., Hiraoka M.: Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode., Radiology, 238(1): 346-53, 2006
   11		Tachiiri S., Katagiri T., Tsunoda T., Oya N., Hiraoka M., Nakamura Y.: Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts., Int J Radiat Oncol Biol Phys, 64(1): 272-9, 2006
   12		Kazawa, N., Kitaichi, M., Hiraoka, M., Togashi, K., Mio, N., Mishima, M., Wada, H.: Small cell lung carcinoma: Eight types of extension and spread on computed tomography., J Comput Assist Tomogr, 30(4): 653-61, 2006
   13		Kawashita M., Takayama T., Kokubo T., Takaoka G.G., Araki N., Hiraoka M.: Enzymatic Preparation of Hollow Yttrium Oxide Microspheres for In Situ Radiotherapy of Deep-Seated Cancer., J.Am. Ceram. Soc., 89(4): 1347-51, 2006
   14		Narabayashi M., Mitsumori M., Araki N., Yamauchi C., Kawamura S., Sakamoto T., Tachiiri S., Oya N., Nagata Y., Hiraoka M., Mise K., Kodama H.: A Case of Metachronous Bilateral Breast Cancer with Bilateral Radiation Pneumonitis After Breast-conserving Therapy., Breast Cancer, 13(3): 313-6, 2006
   15		Aoki T., Takahashi J., Ueba T., Oya N., Hiraoka M., Matsui K., Fukui T., Nakashima Y., Ishikawa M., Hashimoto.: Phase Ⅱstudy of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group., J Neurosurg., 105(3): 385-91, 2006
   16		Kawashita M., Domi S., Saito Y., Aoki M., Ebisawa Y., Kokudo T., Saito T., Takano M., Araki N., Hiraoka M.: In vitro heat generation by ferrimagnetic maghemite microspheres for hyperthemic treatment of cancer under an alternating magnetic field., Submitted to Biomaterials, 2006
   17		Kamino Y., Takayama K., Kokubo M., Narita Y., Hirai E., Kawawda N., Mizowaki T., Nagata Y., Nishidai T., Hiraoka M.: Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head., Int J Radiat Oncol Biol Phys., 66(1):271-8, 2006
   18		Yoshimura M., Kohzaki M., Nakamura J., Asagoshi K., Sonoda E., Hou E., Prasad R., Wilson S. H., Tano K., Yasui A., Lan L., Seki M., Wood R. D., Arakawa H., Buerstedde J. M., Hochegger H., Okada T., Hiraoka M., Takeda S.: Vertebrate POLQ and POLbeta Cooperate in Base Excision Repair of Oxidative DNA Damage., Mol Cell, 24(1): 115-25, 2006
   19		Harada H., Kizaka-Kondoh S., Hiraoka M.: Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564., FEBS Lett., 580(24): 5718-22, 2006
   20		Nishio T., Kunieda E., Shirato H., Ishikura S., Onishi H., Tateoka K., Hiraoka M., Narita Y., Ikeda M., Goka T.: Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403)., Phys Med Biol., 51(21): 5409-17, 2006
   21		Mitsumori M., Sasaki Y., Mizowaki T., Takayama K., Nagata Y., Hiraoka M., Negoro Y., Sasai K., Kinoshita H., Kamoto T., Ogawa O.: Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure., Int J Clin Oncol., 11(5): 396-402, 2006
   22		Yoshimura K., Kamoto T., Nakamura E., Segawa T., Kamba T., Takahashi T., Nishiyama H., Ito N., Takayama K., Mizowaki T., Mitsumori M., Hiraoka M., Ogawa O.: Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy., Prostate Cancer Prostatic Dis., 2006.
   23		Saga T., Kawashima H., Araki N., Takahashi J. A., Nakashima Y., Higashi T., Oya N., Mukai T., Hojo M., Hashimoto N., Manabe T., Hiraoka M., Togashi K.: Evaluation of primary brain tumors with FLT-PET: usefulness and limitations., Clin Nucl Med., 31(12): 774-80., 2006
   24		Kosaka Y., Mitsumori M., Araki N., Yamauchi C., Nagata Y., Hiraoka M., Kodama H.: Avascular necrosis of bilateral femoral head as a result of long-term steroid administration for radiation pneumonitis after tangential irradiation of the breast., Int J Clin Oncol., 11(6): 482-6., 2006
   25		Hiraoka M., Matsuo Y., Nagata Y.: Stereotactic body radiation therapy (SBRT) for early-stage lung cancer., Cancer Radiother, 2006.

   2005

   1		Harada H., Kizaka-Kondoh S., Hiraoka M.: Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals., Mol Imaging, 4(3):182-93, 2005
   2		Liu J., Qu R., Ogura M., Shibata T., Harada H., Hiraoka M.: Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts., J Radiat Res (Tokyo), 46(1): 93-102, 2005
   3		Lyshchik A., Higashi T., Asato R., Tanaka S., Ito J., Hiraoka M., Brill A. B., Saga T., Togashi K.: Elastic moduli of thyroid tissues under compression., Ultrason Imaging, 27(2):101-10, 2005
   4		Lyshchik A., Higashi T., Asato R., Tanaka S., Ito J., Mai J. J., Pellot-Barakat C., Insana M. F., Brill A. B., Saga T., Hiraoka M., Togashi K.: Thyroid gland tumor diagnosis at US elastography., Radiology, 237(1): 202-11, 2005
   5		Mitsumori M., Hiraoka M., Negoro Y., Yamauchi C., Shikama N., Sasaki S., Yamamoto T., Teshima T., Inoue T.: The patterns of care study for breast-conserving therapy in Japan: analysis of process survey from 1995 to 1997., Int J Radiat Oncol Biol Phys, 62(4): 1048-54, 2005
   6		Nagata Y., Takayama K., Matsuo Y., Norihisa Y., Mizowaki T., Sakamoto T., Sakamoto M., Mitsumori M., Shibuya K., Araki N., Yano S., Hiraoka M.: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame., Int J Radiat Oncol Biol Phys., 63(5):1427-31, 2005
   7		Nakayama T., Tsuboyama T., Toguchida J., Tanaka C., Oya N., Hiraoka M., Nakamura T.: Recurrence of osteosarcoma after intraoperative radiation therapy., Orthopedics, 28(10): 1195-7, 2005
   8		Ogura M., Shibata T., Yi J., Liu J., Qu R., Harada H., Hiraoka M.: A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas., Cancer Sci., 96(5): 288-94, 2005
   9		Sai H., Mitsumori M., Araki N., Mizowaki T., Nagata Y., Nishimura Y., Hiraoka M.: Long-term results of definitive radiotherapy for stage I esophageal cancer., Int J Radiat Oncol Biol Phys., 62(5): 1339-44, 2005
   10		Sakamoto G., Inaji H., Akiyama F., Haga S., Hiraoka M., Inai K., Iwase T., Kobayashi S., Sakamoto G., Sano M., Sato T., Sonoo H., Tsuchiya S. Watanabe T.: General rules for clinical and pathological recording of breast cancer 2005., Breast Cancer, 12 Suppl: S1-27, 2005
   11		Takayama K., Nagata Y., Negoro Y., Mizowaki T., Sakamoto T., Sakamoto M., Aoki T., Yano S., Koga S., Hiraoka M.: Treatment planning of stereotactic radiotherapy for solitary lung tumor., Int J Radiat Oncol Biol Phys., 61(5): 1565-71, 2005
   12		Yamauchi C., Mitsumori M., Nagata Y., Kokubo M., Inamoto T., Mise K., Kodama H., Hiraoka M.: Bilateral breast-conserving therapy for bilateral breast cancer: results and consideration of radiation technique., Breast Cancer, 12(2):135-9, 2005
   13		Zhang Z., Harada H., Tanabe K., Hatta H., Hiraoka M., Nishimoto S.: Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging., Peptides, 26(11): 2182-7, 2005
   14		Zhu S., Mizowaki T., Nagata Y., Takayama K., Norihisa Y., Yano S., Hiraoka M.: Comparison of three radiotherapy treatment planning protocols of definitive external-beam radiation for localized prostate cancer., Int J Clin Oncol., 10(6): 398-404, 2005
   15		Karasawa K., Mitsumori M., Yamauchi C., Gomi K., Kataoka M., Uematsu T., Kodaira T., Yamakawa M., Karasawa K., Watanabe T., Tsujino K., Hiraoka M.: Treatment outcome of breast-conserving therapy in patients with positive or close resection margins: Japanese multi institute survey for radiation dose effect., Breast Cancer, 12(2):91-8, 2005
   16		Nishida M., Yasuda S., Murakami K., Yamamura I., Nagata Y., Iizuka T.: Retropharyngeal lymph node metastases from oral cancer: a report of 2 patients., J Oral Maxillofac Surg., 63(3): 410-2, 2005
   17		Vasanthan A., Mitsumori M., Park J. H., Zhi-Fan Z., Yu-Bin Z., Oliynychenko P., Tatsuzaki H., Tanaka Y., Hiraoka M.: Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency., Int J Radiat Oncol Biol Phys., 61(1): 145-53, 2005

   2004

   1		Aoki T.,Nagata Y., Negoro Y., Takayama K., Mizowaki T., Kokubo M., Oya N., Mitsumori M., Hiraoka M.: Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors., CT appearance. Radiology, 230(1):101-8, 2004
   2		Hiraoka M.: Current status of and perspectives on chemoradiotherapy: an introduction., Int J Clin Oncol., 9(6):413, 2004
   3		Hiraoka M., Y. Nagata: Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience., Int J Clin Oncol, 9(5): 352-5, 2004
   4		Inoue M., Mukai M., Hamanaka Y., Tatsuta M., Hiraoka M., Kizaka-Kondoh S.: Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites., Int J Oncol, 25(3):713-20,2004
   5		Ishimori T., Saga T., Nagata Y., Nakamoto Y., Higashi T., Mamede M., Mukai T., Negoro Y., Aoki T., Hiraoka M., Konishi J.: 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy., Ann Nucl Med., 18(8): 669-74, 2004
   6		Li G., Mitsumori M., Ogura M., Horii N., Kawamura S., Masunaga S., Nagata Y., Hiraoka M.: Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma., Int J Clin Oncol., 9(3): 179-83, 2004
   7		Liu J., Shibata T., Qu R., Ogura M., Hiraoka M.: Influences of the p53 status on hypoxia-induced gene expression., J Radiat Res (Tokyo), 45(2): 333-9, 2004
   8		Masunaga S., Nagasawa H., Hiraoka M., Sakurai Y., Uto Y., Hori H., Nagata K., Suzuki M., Maruhashi A., Kinashi Y., Ono K.: Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate TX-2060 as a 10B-carrier in boron neutron capture therapy., Anticancer Res., 24(5A): 2975-83, 2004
   9		Okumura S., Mitsumori M., Yamauchi C., Kawamura S., Oya N., Nagata Y., Hiraoka M., Kokubo M., Mise K., Kodama H.: Feasibility of breast-conserving therapy for macroscopically multiple ipsilateral breast cancer., Int J Radiat Oncol Biol Phys., 59(1): 146-51, 2004
   10		Onishi H., Araki T., Shirato H., Nagata Y., Hiraoka M., Gomi K., Yamashita T., Niibe Y., Karasawa K., Hayakawa K., Takai Y., Kimura T., Hirokawa Y., Takeda A., Ouchi A., Hareyama M., Kokubo M., Hara R., Itami J., Yamada K.: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study., Cancer, 101(7):1623-31, 2004
   11		Sai H., Mitsumori M., Yamauchi C., Araki N., Okumura S., Nagata Y., Nishimura Y., Hiraoka M.: Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil., Int J Clin Oncol., 9(3):149-53, 2004
   12		Sawada A., Yoda K., Kokubo M., Kunieda T., Nagata Y., Hiraoka M.: A technique for noninvasive respiratory gated radiation treatment system based on a real time 3D ultrasound image correlation: a phantom study., Med Phys., 31(2): 245-50, 2004
   13		Shibata T.,Fujimoto Y., Jin M. J.,Hiraoka M.: Transcatheter arterial embolization for large pancreaticoduodenal artery aneurysm with mechanically detachable coils., Cardiovasc Intervent Radiol., 27(2): 169-71, 2004
   14		Shibata T.,Shibata T.,Maetani Y.,Kubo T.,Itoh K.,Togashi K.,Hiraoka M.: Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome., J Vasc Interv Radiol., 15(11): 1323-7, 2004
   15		Masunaga S., Nagasawa H., Hiraoka M., Sakurai Y., Uto Y., Hori H., Nagata K., Suzuki M., Maruhashi A., Kinashi Y., Ono K. The usefulness of 2-nitroimidazole-sodium borocaptate-10B conjugates as 10B-carriers in boron neutron capture therapy., Appl Radiat Isot., 61(5): 953-8,2004
   16		Tabuena R. P., Matsumoto H., Mio T., Nagata Y., Mishima M.: Metastatic tumor in the right atrium., Intern Med., 43(5): 445-6, 2004

   2003

   1		Shibamoto Y., Hayabuchi N., Hiratsuka J., Tokumaru S., Shirato H., Sougawa M., Oya N., Uematsu Y., Hiraoka M.: Is Whole-Brain Irradiation Necessary for Primary Central Nervous System Lymphoma? Patterns of Recurrence after Partial-Brain Irradiation., Cancer, 97(1): 128-133, 2003
   2		Inakoshi H., Kanamori R., Tsuchida E., Sakai K., Shibamoto Y., Wakushima H., Ogawa Y., kobayashi M., Obara, T.: Multivariate Analysis of Dissemination Reapse of Medulloblastoma and Estimation of Its Time Parameter for Craniospinal Irradiation., Radiation Medicine, 21(1): 37-45, 2003
   3		Kinoshita K., Teshima T., Ohno Y., Inoue T., Yamashita T., Hiraoka M., Mitsuhashi N. , Sumi M.: Logical checking function increases the accuracy of data entry in the patterns of care study., Strahlenther Onkol., 179(2): 107-12, 2003
   4		Kawashita M., Kokubo T., Hiraoka M.: Ceramic Microspheres for in Situ Treatment of Cancer, Advances in Sciences and Technology. Materials In Clinical Apprications Ⅵ, Techna Srl, 2003.
   5		Mizowaki T., Okajima K., Nagata Y., Mitsumori M., Nishimura Y., Shoji K., Asato R., Hiraoka M.: Concurrent chemotherapy and radiotherapy with Low-Dose cisplatin for nasopharyngeal carcinoma., Am. J. Clin. Oncol. (CCT), 26(2): 155-8, 2003
   6		Kawashita M., Shineha R., Kim H. M., Kokubo T., Inoue Y., Araki N., Nagata Y., Hiraoka M., Sawada Y.: Preparation of ceramic microspheres for in situ radiotherapy of deep-seated cancer., Biomaterials., 24(17): 2955-2963, 2003.
   7		Suzuki M., Nakamatsu K., Kanamori S., Okumura M.: Feasibility Study of the Simultaneous Integrated Boost (SIB) Method for Malignant Gliomas Using Intensity-modulated Radiotherapy (IMRT)., Jpn J Clin Oncol., 33(6): 271-77, 2003
   8		Nishimura Y., Nagata K., Katano S., Sai H.: Severe Complication in Advanced Esophageal Cancer Treated with Radiotherapy after Intubation of Esophageal Stents: A Questionnaire Survey of the Japanese Society for Esophageal Diseases., Int J. Radiation Oncology Biol. Phys., 56(5): 1327-32, 2003
   9		Shikama N., Sasaki S., Mitsumori M., Hiraoka M., Yamauchi C., Yamamoto T., Teshima T. and Inoue T.: Patterns of Care Study in Japan: Analysis of patients subjected to mastectomy followed by radiotherapy., Jpn. J Clin. Oncol., 33(9):456-62, 2003
   10		Ogura M., Mitsumori M., Okumura S., Yamauchi C., Kawamura S., Oya N., Nagata Y., Hiraoka M.: Radiation therapy for brain metastases from breast cancer., Breast Cancer, 10 (4): 349-55, 2003
   11		Kizaka-Kondoh S., Inoue M., Harada H., Hiraoka M.: Tumor hypoxia:A target for selective cancer therapy., Cancer Science, 94(12):1021-28, 2003
   12		Okamoto T., Shimozuma K., Katsumata N., Koike M., Hisashige A., Tanaka K., Ohsumi S., Saito M., Shikama N., Mitsumori M., Yamauchi C., Watanabe T.: Measuring quality of life in patients with breast cancer:A systematic review of reliable and valid instruments available in Japan., Breast Cancer, 10 (3):204-12, 2003
   13		Okumura S.,Mitsumori M., Kokubo M., Yamauchi C., Kawamura S., Oya N., Nagata Y., Hiraoka M.: Late skin and subcutaneous soft tissue changes after 10-Gy boost for breast conseving therapy., Breast Cancer, 10(2):129-33, 2003
   14		Ikeda H.: Non-invasive manegement of invasive bladder cancer: Lectures by professor William U. Shipley., Jpn J Clin Oncol, 33 (11): 592-94, 2003
   15		Yakami M., Mitsumori M., Sai H., Nagata Y., Hiraoka M., Nishimura Y.: Developmento of severe complications caused by stent placement followed by definitive radiation therapy for T4 esophageal cancer., Int J Clin Oncol., 8(6):395-8, 2003
   16		Shibata T.,Yamamoto Y., Yamamoto N.,Maetani Y., Shibata T., Ikai I., Terajima H., Hatano E.., Kubo T., Itoh K., Hiraoka M.: Cholangitis and Liver Abscess after Percutaneous Ablation Therapy for Liver Tumors: Incidence and Risk Factors., J. Vasc. Interv. Radiol., (14): 1535-42, 2003
   17		Ogura M., Shibata T., Qu R., Liu J., Yi J., Hiraoka M.: A tumor-specific gene therapy for renal cell carcinomas using a hypoxia-responsive vector system., Int J Radiat Oncol Biol Phys., 57(2 Suppl): S345-6, 2003
   18		Aoki T., Nagata Y., Mizowaki T., Kokubo M., Negoro Y., Takayama K., Mitsumori M., Sasai K., Hiraoka M.: Clinical evaluation of dynamic arc conformal radiotherapy for paraaortic lymph node metastasis., Radiotherapy and oncology, 67(1): 113-8, 2003
   19		Shikama N., Nishikawa A., Mitsumori M., Hiraoka M., Yamamoto T., Teshima T., Inoue T., Wilson F., Owen J.: Patterns of care study: comparison of process of post-mastectomy radiotherapy (PMRT) in Japan and the USA., Jpn J Clin Oncol., 33(10): 518-21, 2003

   2002

   1		Nagata Y., Negoro Y., Aoki T., Mizowaki T., Takayama K., Kokubo M., Araki N., Mitsumori M., Sasai K., Shibamoto Y., Koga S., Yano S., Hiraoka M.: Clinical outcomes of 3-D conformal hypofractionated single high dose radiotherapy for one of two lung tumors using a stereotactic body frame., Int. J. Radiat. Oncol. Biol. Phys., 52(4):1041-46, 2002
   2		Oya N., Shibamoto Y., Nagata Y., Negoro Y., Hiraoka M.: Postperative radiotherapy for intracranial ependymoma:analysis of prognostic factors and patterns of failure., J. of Neuro-Oncol., 56(1):87-94, 2002
   3		Harada H., Hiraoka M., Kizaka-Kondoh S.: Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells., Cancer Research, 62(7): 2013-18, 2002
   4		Nishimura Y., Suzuki M., Nakamatsu K., Kanamori S., Yagyu Y., Shigeoka H.: Prospective Trial of Concurrent Chemoradiotherapy with Protracted Infusion of 5-Fluorouracil and Cisplatin for T4 Esophageal Cancer With or Without Fistula., Int.J.Radiation Oncol. Biol. Phys., 53(1):134-9, 2002
   5		Shibamoto Y., Oya N., Kokubo M., Hiraoka M., Doi, R., Tsujitani M.: Intraoperative Radiotherapy using Hypoxic Cell Sensitizers: Japanese Clinical Trials., Progress in Radio-Oncol. Ⅶ, (Salzburg, Austria, May 15-19.2002):333-9, 2002
   6		Hiraoka M., Mitsumori M. and Shibuya K.: Adjuvant radiation therapy following mastectomy for breast cancer., Breast Cancer, 9(3):190-5, 2002
   7		Takata M., Tachiiri S., Fujimori A., Larry H. Thompson, Miki Y., Hiraoka M., Takeda S., Yamazoe M.: Conserved domains in the chicken homologue of BRCA2, Oncogene 21, 1130-34, 2002
   8		Hiraoka M., Kokubo M., Yamamoto C., Mitsumori M.: Current Status and Perspectives of Radiation Therapy for Breast Cancer., JMAJ, 45(10):434-39, 2002

   2001

   1		Araki N., Nagata Y., Fujiwara K., Aoki T., Mitsumori M., Kimura H., Itasaka S., Saitou H., Hiraoka M., Kawashita M., Kokubo T.: Evaluation of glass microspheres for intra-arterial radiotherapy in animal kidneys., Int. J. Radiat. Oncol. Biol. Phys., 49(2): 459-63, 2001
   2		Negoro Y., Nagata Y., Aoki T., Mizowaki T., Araki N., Takayama K., Kokubo M., Yano S., Koga Y., Sasai K., Shibamoto Y., Hiraoka M.: The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of daily set-up accuracy., Int J Radiat Oncol Biol Phys., 50(4): 889-98, 2001
   3		Horii N., Nishimura Y., Okuno Y., Kanamori S., Hiraoka M., Shimada Y., Imamura M.: Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas., Int.J. Radiation Oncology Biol. Phys.,49(2):527-32, 2001
   4		Mizowaki T., Araki N., Nagata Y., Negoro Y., Aoki T., Hiraoka M.: The use of a permanent magnetic resonance imaging system for radiotherapy treatment planning of bone metastases., Int. J. Radiat. Oncol. Biol. Phys., 49(2): 605-11, 2001
   5		Shibamoto Y., Sasai K., Oya N., Hiraoka M.: Intracranial germinoma : radiation therapy with tumor Volume-based dose selection1., Radiology , 218(2): 452-6, 2001
   6		Ueda T., Akiyama N., Sai H., Oya N., Noda M., Hiraoka M., Kizaka-Kondoh S.: c-IAP2 is induced by ionizing radiation through NF-κB binding sites., FEBS Letters , 491(1-2): 40-4, 2001
   7		Tamai K., Mitsumori M., Fujishiro S., Kokubo M., Oya N., Nagata Y., Sasai K., Hiraoka M., Inamoto T.: A case of allergic reaction to surgical metal clips inserted for postoperative boost irradiation in a patient undergiong breast-conserving therapy., Breast Cancer, 8(1): 90-2, 2001
   8		Yu H., Mitsumori M., Nagata Y., Katakura Y., Kokubo M., Oya N., Fujishiro S., Sasai K., Hiraoka M., Kan N.: Meningeal carcinomatosis in patients with breast cancer : Report of 8 Patients., Breast Cancer, 8(1): 74-78, 2001
   9		Hiraoka M., Mitsumori M., Nagata Y., Horii N., Kanamori S., Kimura H., Okumura S., Okuno Y., Koishi M., Masunaga S., Akuta K., Nishimura Y.: Current status of clinical hyperthermic oncology in Japan., Thermotherapy for neoplasia, inflammation, and pain, Springer, 2001
   10		Koishi M., Yokota S., Mae T., Nishimura Y., Kanamori S., Horii N., Shibuya K., Sasai K., Hiraoka M.: The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo., Clin. Cancer Res.,7(1): 215-9, 2001
   11		Kokubo M., Nagata Y., Nishimura Y., Kimura H., Shoji K., Asato R., Sasai K., Hiraoka M.: Concurrent chemoradiotherapy for oropharyngeal carcinoma., Am. J. Clin. Oncol.(CCT), 24(1): 71-76, 2001
   12		Imai A., Teshima T., Ohno Y., Inoue T., Yamashita T., Mitsuhashi N., Hiraoka M., Sumi M., the Japanese PCS Working Group: The future demand for and structural problems of Japanese radiotherapy., Jpn. J. Clin. Oncol., 31(4): 135-41, 2001
   13		Tingyi Xia, Qingxuan Sun, Xiaoli Shi, Naibin Fan, Hiraoka M.: Relationship between thermal parameters and tumor response in hyperthermia combined with radiation therapy., Int. J. Clin. Oncol., 6: 138-42, 2001
   14		Oya N., Sasai K., Shibata T., Takagi T., Shibuya K., Koike s., Nojima K., Fukusawa Y., Ando K., Hiraoka M.: Time course of reoxygenation in experimental murine tumors after Carbon-beam and X-ray irradiation., J. Radiat. Res., 42(2): 131-41, 2001
   15		Hayashi M., Teshima T., Tanisada K., Ohno Y., Inoue T., Hiraoka M., Yamashita T., Mitsuhashi N., Sumi M., Japanese working group: Automatic search for optimal conditions in clinical studies., Anticancer Res., 21: 1371-74, 2001
   16		Sakamoto T., Kokubo M., Sasai K., Chin K., Jun A. Takahashi, Nagata Y., Hiraoka M.: Central neurogenic hyperventilation with primary cerebral lymphoma: A case report., Rad. Med., 19(4):209-13, July-August 2001
   17		Sasai K., Yamabe H., Dodo Y., Kashii S., Nagata Y. and Hiraoka H.: Non-Hodgkin’s lymphoma of the ocular adnexa., Taylor Francis, 40(4):485-90, 2001
   18		Hori T., Kodama H., Nishimura S., Hatano T., Okamura R., fujii K., Kudo T., Inamoto T., Sawai K., Kobayashi M., Ogawa H., Yoshimura N., Hiraoka M.: A randomized study comparing oral and standard regimens for metastatic breast cancer., Oncol. Reports, 8(5), 1067-71, 2001
   19		Fujimori A., Tachiiri S., Sonoda E., Larry H. Thompson, Pawan Kumar Dhar, Hiraoka M., Takeda S., Yong Zhang., Michael Reth ,Takata M.: Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells., The EMBO Journal, 20(19): 5513-20, 2001
   20		Mitsumori M., Shibata T.,Nagata Y.,Hiraoka M., Hasegawa M.,Nagae H., Kito K.: Time Course Change of the Heart-generating Capability of Dextran Magnetite Complex (DM) in vivo, Jpn., J. Hyperthermic Oncol., .17(2):85-92, 2001June
   21		Kokubo M., Mitsumori M., Yamamoto C., Fujishiro S., Mise K., Kodama H., Nagata Y. and Hiraoka M.: Impact of boost irradiation with surgically placed radiopaque clips on lical control in breast-conseving therapy., Breast Cancer, 8(3): 222-28, 2001
   22		Hinata H., Inakoashi H., Sakai K., Ogawa Y., Kobayashi M., Wakushima H., obara T., Shibamoto Y.: Estimation of Time Parameter of LQ-model in Fractionated Radiotherapy of Medulloblastoma, Radiation Medicine, 19(2):61-70, 2001
   23		Kokubo M., Mitsumori M., Kanehira K., Inamoto T.,Mise K., Kodama H., Yamabe H., Hiraoka M.: Results of breast-conserving therapy for ductal carcinoma in situ:The Kyoto University experiences, Breast Cancer, 8(2):153-57, 2001
   24		Oya N., Kokubo M, Mizowaki T, Shibamoto Y, Nagata Y, Sasai K, Nishimura Y, Tsuboyama T, Toguchida J, Nakamura T, Hiraoka M.: Defenitive intraoperative very high-dose radiotherapy for localized osteosarcoma in extremities., Int. J. Radiation Oncology Biol. Phys., 51(1):87-93, 2001
   25		Umetani K., Itasaka S., Ogura M., Kimura H., Hiraoka M.: Synchrotron Radiation Microangiography System for Observation of Blood Flow in Murine Tumor Vasculature., Bioimages, 9(3-4): 97-106, December 2001
   26		Tsukiyama I., Katano S., Shimizu H., Nomoto Y., Shoji K., Hiraoka M., Mitsumori M., Tanaka Y., Nagata K., Fuwa N., Mitsuhashi N., Sakurai H.: Multi-institutional Phase I and ⅡTrial of Simultaneous Intracavitary Hyperthermia and Brachytherapy for Advanced Esophageal Cancer, J Brachytherapy Int, 17: 299-308, 2001
   27		Hayashi M., Teshima T., Tanisada K., Ohno Y., Inoue T., Hiraoka M., Yamashita T., Mitsuhashi N., Sumi M.: Automatic search for optimal conditions in clinical studies., Anticancer Res., 21(2B): 1371-4, 2001
   28		Imai A., Teshima T., Ohno Y., Inoue T., Yamashita T., Mitsuhashi N., Hiraoka M., Sumi M.: The future demand for and structural problems of Japanese radiotherapy., Jpn J Clin Oncol., 31(4): 135-41, 2001
   29		Xia T., Sun Q., Shi X., Fan N., Hiraoka M.: Relationship between thermal parameters and tumor response in hyperthermia combined with radiation therapy., Int J Clin Oncol., 6(3): 138-42, 2001

   2000

   1		Zhu J.L., Nagata Y., Kanamori S., Mitsumori M., Okuno Y., Horii N., Nishimura Y., Masunaga S., Hiraoka M.: Prelimimary Clinical Results of Locoregional Hyperhermia for Primary and Secondary Bone Tumors., Jpn. J. Hyperther. Oncol. 16: 17-26, 2000
   2		Nagata Y., Araki N., Kimura H., Fujiwara K., Okajima K., Aoki T., Mitsumori M., Sasai K., Hiraoka M., Higuchi T., Fujii S.: Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer., JVIR 11（３）: 313-19, 2000
   3		Tanisada K., Teshima T., Ikeda H., Abe M., Owen J.B., Hanks G.E., Yamashita T., Nishio M., Yamada S., Sakai K., Hiraoka M., Hirokawa Y., Oguchi M., Inoue T.: A preliminary outcome analysis of the patterns of care study in Japan for esophageal cancer patients with special reference to age : Non surgery group., Int. J. Radiat. Oncol. Biol. Phys., 46(5): 1223-33, 2000
   4		Fujishiro S., Mitsumori M., Kokubo M., Nagata Y., Sasai K., Mise K., Kodama H., Hiraoka M.: Cosmetic results and complications after breast conseving therapy for early breast cancer., Breast Cancer, 7: 57-63, 2000
   5		Sasai K., Nagata Y., Hiraoka M.: Is the linear-quadratic formula available in stereotactic radiosurgery or hypofractionated radiotherapy? The problem of uncertainty of the a/b ratio in the LQ formula., Int. J. Radiat. Oncol. Biol. Phys., 47: 1157-58, 2000
   6		Sasai K., Yamabe H., Kokubo M., Shibata T., Oya N., Nagata Y., Hiraoka M.: Head and neck stages I and II extranodal non-Hodgkin’s lymphomas:Head and neck stages I and II extranodal non-Hodgkin’s lymphomas:REALclassification and selection for treatment modality., Int. J. Radiat. Oncol. Biol. Phys.,48(1): 153-60, 2000
   7		Nagata Y., Nishidai T., Hiraoka M.: Development of a CT simulator and its current clinical situations., J. Jpn. Soc. Ther. Radiol. Oncol., 12: 95-108, 2000
   8		Kokubo M., Sasai K., Shibamoto Y., Oya N., Mitsumori M., Jun A. Takahashi, Hashimoto N., Hiraoka M.: Long-Term Results of Radiation Therapy for Pituitary Adenoma., J Neurooncol ,47(1):79-84, 2000
   9		Fujiwara K., Hayakawa K., Nagata Y., Hiraoka M., Nakamura T., Shimizu Y., Ikada Y.: Experimental Embolization of Rabbit Renal Arteries to Compare the Effects of Poly L-lactic Acid Microspheres With and Without Epirubicin Release Against Intraarterial Injection of Epirubicin., Cardiovasc Intervent Radiol, 23(3):218-223, 2000
   10		Kokubo M., Nishimura Y., Shibamoto Y., Sasai K., Hosotani R., Imamura M., Hiraoka M.: Concurrent chemoradiotherapy combined with intraoperative radiotherapy for locally advanced pancreatic cancer:A feasibility study.. Oncology Reports,7(4):773-76, 2000
   11		Xie X., Sasai K., Shibuya K., Tashiiri S., Nihei K., Ohnishi T., Hiraoka M.,: P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative., Cancer-Chemother-Pharmacol., 45(5):362-8, 2000
   12		Kokubo M., Shibamoto Y., Jun A Takahashi, Sasai K., Oya N., Hashimoto N., Hiraoka M.: Efficacy of conventional radiotherapy for recurrent meningioma., Journal of Neuro-Oncology, 48(1):51-55,2000
   13		Mizowaki T., Nagata Y., Okajima K., Kokubo M., Negoro Y., Araki N., Hiraoka M.: Reproducibility of geometric distortion in magnetic resonance imaging based on phantom studies., Radiotherapy and Oncology, 57(2): 237-242, 2000
   14		Hiraoka M.,Mitsumori M., Nagata Y.,Horii N., Kanamori S., Kimura H., Okumura S., Okuno Y., Koishi M., Masunaga S., Akuta K., Nishimura Y.: Current Status of Clinical Hyperthemic Oncology in Japan. Thermotherapy for Neoplasia, Inflammation, and Pain,Springer, 471-479,2000
   15		Kokubo, M., Nishimura, Y., Shibamoto, Y., Sasai, K., Kanamori, S., Hosotani, R., Imamura, M., Hiraoka M.: Analysis of the Clinical Benefit of Intraoperative Radiotherapy in Patients undergoing Macroscopically Curative Resection for Pancreatic Cancer., Int. J. Radiat. Oncol. Biol. Phys., .48(4):1081-87, 2000
   16		Miyakoshi J., Yoshida M., Shibuya K., Hiraoka M.: Exposure to Strong Magnetic Fields at Power Frequency Potentiates X-ray-induced DNA Strand Breaks., J. of Rad. Res., 41(3):293-302, 2000
   17		Kokubo, M., Mitsumori, M., Ishikura, S., Nagata, Y., Fujishiro, S., Inamoto, T., Mise, K., Kodama, H., Sasai, K., Hiraoka M.: Results of Breast-Conserving Therapy for Early Stage Breast Cancer: Kyoto University Experiences., Am. J. Clin. Oncol (CCT), 23(5):499-505,2000
   18		Noma S., Mizowaki T., Kubo T., Kirihara M., Akasaka Y, Taniguchi T., Sano A., Kuroda Y.: Marking a small pulmonary nodule with a new point marker for thoracoscopic resection., Jpn J Clin. Radiol., 45(1):79-84, 2000
   19		Mizowaki T., Yoden E., Nishimura S., Kobashi Y., Kirihara M., Akasaka Y., Okamoto Y., Murakami M., Noma S., Kuroda Y., Nakajima T.: Stereotactic biopsy of non-palpable breast lesions with microcalcifications., Jpn J Breast Cancer, 15(4):428-35, 2000
   20		Okamoto Y., Murakami M., Kuroda M., Mizowaki T., Nakajima T., Kusumi F., Hajiro K., Matsusue S., Takeda H., Kobashi, Y.: Mismatched clinicopathological response after concurrent chemoradiotherapy for thoracic esophageal cancer., Dis Esophagus, 13(1): 80-86, 2000
   21		Tachiiri S., Sasai K., Oya N., Hiraoka M.: Enhanced Cell Killing by Overexpression of Dominant-negativePhosphatidylinositol 3-Kinase Subunit, Δp85, Following Genotoxic Stresses., JapaneseJournal of Cancer Research, 91(12):1314-18, December 2000
   22		Tsuboyama T., Toguchiba J., Kotoura Y., Kasahara K., Hiraoka M., Nakamura T.: Intra-operative radiation therapy for osteosarcoma in the extremities., Int. Orthopaedics(SICOT), 24(4): 202-7, 2000
   23		Hiraoka M.,Mitsumori M., Horii N., Ohno S., Tanaka Y., Kotsuka Youji., Senior Member IEEE, Sugimachi K.: Development of RF and Microwave Heating Equipment and Clinical Applications to Cancer Treatment in Japan., IEEE Transaction on Microwave Theory and Techniques, .48(11): 1789-99, Nov. 2000
   24		Nishimura M., Tsukahara H., Hiraoka M., Osaka Y., Ohshima Y., Tanizawa A., Mayumi M.: Systemic inflammatory response syndrome and acute renal failure associated with Hemophilus influenzae septic meningitis., Am J Nephrol., 20(3): 208-11, 2000
   25		Nihei K., Mitsumori M., Ishigaki T., Fujishiro S., Kokubo M., Nagata Y., Sasai K., Hiraoka M.: Determination of optimal radiation energy for different breast sizes using CT-simulator [correction of simulatior] in tangential breast irradiation., Breast Cancer, 7(3): 231-6, 2000

   1999

   1		Nishimura Y., Yokoe Y., Nagata Y., Okajima K., Nishida M. and Hiraoka M.: High-dose-rate brachytherapy using molds for oralcavity cancer., Int. J. Clin. Oncol., 3: 351-56, 1998
   2		Teshima T., Ikeda H., Abe M., Hanks G.E., Owen J.B., Oguchi M., Hirokawa Y., Hiraoka M., Nishio M., Yamashita T., Naito A., Okazaki Y., Inoue T.: Patterns of care study of radiation therapy for utereine cervix cancer in Japan: The influence of age on the process., Int. J. Clin. Oncol., 4: 9-16, 1999
   3		Yamamoto M., Nagata Y., Okajima K., Ishigaki T., Murata R., Mizowaki T., Kokubo M. and Hiraoka M.: Differences in target outline delineation from CT scans of brain tumours using different methods and different observers., Radiother. Oncol., 50(2):151-56, 1999
   4		Nagata Y., Okajima K., Kokubo M., Kanamori S., Fujiwara K., Mizowaki T., Sasai K., Hiraoka M., Kataoka N., Konishi I.: Clinical results of transcatheter arterial infusion for uterine cervical cancer., Am. J. Clin. Oncol., 22(1): 97-102, 1999
   5		Tanisada K., Teshima T., Inoue T., Owen J.B., Hanks G.E., Abe M., Ikeda H., Sato S., Kawachi K., Yamashita T., Nishio M., Hiraoka M., Hirokawa Y., Oguchi M. and Masuda K.: National average for the process of radiation therapy in Japan by Patterns of Care Study., Jpn. J. Clin. Oncol., 29(4): 209-13, 1999
   6		Kanamori S., Nishimura Y., Kokubo M., Sasai K., Hiraoka M., Shibamoto Y., Hosotani R., Imamura M., Abe M.: Tumor response and patterns of failure following intraoperative radiotherapy for unresectable pancreatic cancer; Evaluation by computed tomography., Acta Oncolologica, 38(2): 215-20, 1999
   7		Ishikawa S., Nagata Y., Mitsumori M., Sasai K., Kokubo M., Hiraoka M., Tanaka T., Fukumoto M.: Primary large cell carcinoma of the submandibular gland., Int. J. Clin. Oncol., 4: 189-92, 1999
   8		Shibamoto Y., Sasai K., Oya N., Hiraoka M.: Systemic chemotherapy with vincristine, cyclophophamide, doxorubicin and predonisolone following radiotherapy for primary central nervous system lymphoma: a phase II study., J. Neuro-oncol., 42(2): 161-67, 1999
   9		Kanamori S., Nishimura Y., Okuno Y., Horii N., Saga T., Hiraoka M.: Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor., Int. J. of Hyperthermia, 15(4): 267-78, 1999
   10		Okuno Y., Nishimura Y., Kashu I., Ono K., Hiraoka M.: Prognostic values of proliferating cell nuclear antigen(PCNA) and LI-67 for radiotherapy of esophageal squamous cell carcinomas., Brit. J. Cancer, 80（３-4）: 387-95, 1999
   11		Guo G.Z., Sasai K., Oya N., Shibata T., Shibuya K., Hiraoka M.: A significant correlation between clonogenic radiosensitivity and the simultaneous assessment of micronucleus and apoptotic cell frequencies., Int. J. Radiat. Biol., 75（７）: 857-864, 1999
   12		Nishimura Y., Okuno Y., Ono K., Nagata Y., Hiraoka M.: External beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for patients with superficial esophageal carcinoma., Cancer, 86(2): 220-28, 1999
   13		Saitoh H., Nagata Y., Mitsumori M., Kokubo M. and Hiraoka M.: Angiographic changes in uterine cervical cancer guring the course of transarterial infusion chemotherapy., Radiat. Medicine, 17(4): 305-9, 1999
   14		Shibuya K., Sasai K., Xie X., Utsumi H., Shibata T., Hiraoka M.: Detection of hypoxic cells inmurine tumors using the comet assay: comparison with a conventional radiobiological assay., Jpn. J. Cancer Res., 90(8): 880-86, 1999
   15		Mitsumori M., Hiraoka M., Kodama H.: Long-term results of postoperative prophylactic irradiation for node-positive, high-risk breast cancer patients., Breast Cancer, 6(3): 193-200, 1999
   16		Shibuya K., Fujibayashi Y., Yoshimi E., Sasai K., Hiraoka M., Welch M.J.: Cytosolic/microsomal redox pathway: a reductive retention mechanism of a PET-oncology tracer, Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM)., Ann. Nucl. Med., 13(5): 287-92, 1999
   17		Shibamoto Y., Sasai K., Kokubo M., Hiraoka M.: Salvage radiation therapy for intracranial germinoma recurring after primary chemotherapy., J. Neuro-Oncol., 44(2):181-85, 1999
   18		Higashi T., Sakahara H., Torizuka T., Nakamoto Y., Kanamori S., Hiraoka M., Imamura M., Nishimura Y., Tamaki N., Konishi J.: Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET., J Nucl Med., 40(9):1424-33, 1999
   19		Fujishiro S., Mitsumori M., Kokubo M., Nagata Y., Sasai K., Kodama H., Hiraoka M.: Evaluation of long-term cosmetic results and complications following breast conseving surgery and radiation therapy for breast cancer., J Jpn. Soc. Ther. Radiol. Oncol. 11: 287-94, 1999
   20		Shibuya K., Nagata Y., Itoh T., Okajima K., Murata R., Takagi T., Hiraoka M.: Transcatheter arterial infusion therapy in the treatment of advanced pancreatic cancer: a feasibility study., Cardiovasc Intervent Radiol, 22(3): 196-200, 1999
   21		Ikeda T., Akiyama F., Hiraoka M., Inaji H., Ohuchi N., Takatsuka Y., Yoshimoto M.: Surgical Margin Status as a Cause of Local Failure after Breast Conserving Therapy., Breast Cancer, 6(2): 93-97, 1999

   1998

   1		Ikeda T., Akiyama F., Hiraoka M., Inaji H., Ohuchi N., Takatsuka Y., Yoshimoto M.: The current status of the treatment of ductal carcinoma in situ of Japanese women, especially breast conserving operation in relation to the surgical margin and short term outcome., Breast Cancer, 5(1): 53-58, 1998
   2		Guo G.Z., Sasai K., Oya N., Takagi T., Shibuya K. and Hiraoka M.: Simultaneous evaluation of radiation-induced apoptosis and micronuclei in five cell lines., Int. J. Radiat. Biol., 73(3): 297-302, 1998
   3		Nagata Y., Fujiwara K., Okajima K., Mitsumori M., Mizowaki T., Ohya N., Hiraoka M., Abe M., Ohura K., Wataya S.: Transcatheter arterial embolization for malignant osseous and soft-tissue sarcomas. I. A rabbit experimental model., Cardiovasc, Intervent. Radiol., 21(3): 205-7, 1998
   4		Nagata Y., Mitsumori M., Okajima K., Mizowaki T., Fujiwara K., Sasai K., Nishimura Y., Hiraoka M., Abe M., Shimizu K., Kotoura Y.: Transcatheter arterial mbolization for malignant osseous and soft-tissue sarcomas. II. Clinical results., Cardiovasc, Intervent. Radiol., 21(3): 208-13, 1998
   5		Kokubo M., Tsutsui K., Nagata Y., Okajima K., Katakura Y., Negoro Y., Yamamoto M., Hiraoka M.: Radiotherapy combined with transcatheter arterial infusion chemotherapy for locally advanced cervical cancer., Acta Oncolologica, 37(2): 143-49, 1998
   6		Teshima T., Abe M., Ikeda H., Hanks G.E., Owen J.B., Hiraoka, M., Hirokawa Y., Oguchi M., Nishio M., Yamashita T., Niibe H., Masuda K., Watanabe S., Inoue T.: Patterns of care study of radiation therapy for esophageal cancer in Japan: Influence of the stratification of institute on the process., Jpn. J. Clin. Oncol., 28(5): 308-13, 1998
   7		Fujishiro S., Mitsumori M., Nishimura Y., Okuno Y., Nagata Y., Hiraoka M., Sano T, Marume T., Takayama N.: Increased heating efficiency of hyperthermia using an ultrasound contrast agent: a phantom study., Int. J. Hyperthermia, 14(5): 495-502, 1998
   8		Takagi T., Sasai K., Shibamoto Y., Akagi K., Oya N., Shibata T., Kim J., Hiraoka M.: The influence of DNA ploidy of a human tumor cell line on the frequencies of micronuclei or chromosome aberrations after irradiation., Mut. Res. /gen. tox. Env. mut. 418 (1): 49-57, 1998
   9		Shibata T., Akiyama N., Noda M., Sasai K., Hiraoka M.: Enhancement of gene expression under hypoxic conditions using fragment of the human vascular endothelial growth factor and the erythropoietin genes., Int. J. Radiat. Oncol. Biol. Phys., 42(4): 913-16, 1998
   10		Sasai K, Guo G.Z., Shibuya K., Oya N., Shibata T., Nagata Y., Hiraoka M.: Effects of SN-38 ( an active metabolite of CPT-11) on responses of human and rodent cells to irradiation., Int. J. Radiat. Oncol. Biol. Phys., 42(4), 785-88, 1998
   11		Nishio T., Teshima T., Abe M., Ikeda H., Oguchi M., Hirokawa Y., Hiraoka M., Inoue T., Yamashita T., Nishio M., Niibe H., Mori T., Masuda K., Haruuchi H., Inamori K.: Consistency of variables in PCS and JASTRO great area database., Radiation Medicine, 16(6): 449-55, 1998.
   12		Tanisada K., Teshima T., Abe M., Ikeda H., Oguchi M., Hirokawa Y., Hiraoka M., Inoue T., Yamashita T., Yamada S., Sakai K., Nishimura T., Chatani M.: Prognostic factors for patients with esophageal cancer treated with radiation therapy in PCS: A preliminary study., Radiation Medicine, 16(6): 461-68, 1998.
   13		Konishi I, Nanbu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y, Mori T.: Tumor response to nepadjyuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-kappa in the tumor cells of cervical carcinoma., Gynecol Oncol , 70, 365-71, 1998.

   1997

   1		Masunaga S., Ono K, Hiraoka M., et al.: Reduction of hypoxic cells in solid tumours induced by mild hyperthermia:special reference to differences in changes in the hypoxic fraction between total and quiescent cell populations., Br.J.Cancer, 76(5): 588-93, 1997
   2		Murata R., Nishimura Y., Hiraoka M.: An anti-angiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma., Int J. Radiat. Oncol. Biol. Phys., 37(5): 1107-13, 1997
   3		Nagata Y., Hiraoka M., Nishimura Y., Masunaga S., Mitsumori M., Okuno Y., Fujishiro M., Kanamori S., Horii N., Akuta K., Sasai K., Abe M., and Fukuda Y.: Clinical Results of Radiofrequency Hyperthermia for Maglinant Liver Tomors., Int.J.Radiation Oncology Biol. Phys., 38(2): 359-65, 1997
   4		Nishimura Y, Hosotani R, Shibamoto Y, Kokubo M, Kanamori S, Sasai K, Hiraoka M, Ohshio G, Imamura M, Takahashi M, Abe M.: External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications., Int J Radiat Oncol Biol Phys., 1;39(1): 39-49, 1997
   5		Hosotani R., Kogire M., Hiraoka M., et al.: Results of pancreatectomy with radiation therapy for pancreatic cancer., Hepato- Gastroenterology, Nov-Dec.44(18): 1528-35, 1997
   6		Kokubo M., Nagata Y., Mizowaki T., Hiraoka M., Yamamoto M.: Dose-Volume Histogram Analysis of External-Beam Irradiation Combined with IORT for Unresectable Pancreatic Cancer. Veath JM (ed): Intraoperative Radiation Therapy in the Treatment of Cancer., Front Radiat Ther Oncol. Basel, Karger, 31: 177-80, 1997
   7		Sasai K., Yamabe H., Tsutsui K., Dodo Y., Ishigaki T., Shibamoto Y., Hiraoka M.: Primary testicular non-Hodgkin’s lymphoma: a clinical study and review of the literature., Am J Clin Oncol, 20(1): 59-62, 1997
   8		Sasai K., Murata R., Mandai M., Takahashi M., Ogura Y., Ngata Y., Nishimura Y., Hiraoka M.: Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report., Int J Radiat Oncol Biol Phys., 39(1): 173-8, 1997
   9		Nishimura Y., Shibamoto Y., Hosotani R., Ohshio G., Kokubo M., Kanamori S., Sasai K., Hiraoka M., Imamura M., Abe M.: IORT for pancreatic cancer: the Kyoto University experience., Front Radiat Ther Oncol., 31: 184-8, 1997
   10		Nakayama M., Sakahara H., Minowa Y., Sasai K., Ishigaki T., Saga T., Nakamoto Y., Yao Z., Hiraoka M., Sakai K., Konishi J.: Value of low-dose gallium-67 imaging in detection of non-Hodgkin’s lymphoma recurrence., Radiat Med., 15(2): 79-83, 1997
   11		Kanamori S., Nishimura Y., Kokubo M., Hiraoka M., Abe M.: CT changes following IORT for unresectable pancreatic cancer., Front Radiat Ther Oncol., 31: 189-92, 1997
   12		Hiraoka M., Mitsumori M., Kokubo M.: The Roles and Controversies of Radiation Therapy in Breast Conserving Therapy for Breast Cancer., Breast Cancer, 4(3): 127-133, 1997
   13		Akagi M., Tsuboyama T., Ikenaga M., Matsusue Y., Hiraoka M., Nakamura T.: Anti-tumour effects of localized hyperthermia on an experimental bone tumour using an intramedullary nail., Int J Hyperthermia, 13(4): 387-400, 1997

   1996

   1		Masunaga S., Ono K., Mitsumori M., Nishimura Y., Hiraoka M., Akuta K., Nagata Y., Abe M., Takahashi M., Jo S.: Clinical usefulness of determining the rate of thermal clearance within heated tumors., Jpn J Clin Oncol, 26(6): 428-37, 1996
   2		Mitsumori M., Hiraoka M., Okuno Y., Nishimura Y., Y.P. Li, Fujishiro S., Nagata Y., Abe M., Koishi M., Sano T., Marume T., Takayama N.: A phase I and II clinical trial of a newly developed ultrasound hyperthermia system with an improved planar transducer., Int J Radiat Oncol Biol Phys, 36(5): 1169-75, 1996
   3		Mitsumori M., Hiraoka M., Shibata T., Okuno Y., Nagata Y., Nishimura Y., Abe M., Hasegawa M., Nagae H., Ebisawa Y.: Targeted hyperthermia using dextran magnetite complex: a new treatment modality for liver tumors., Hepatogastroenterology, 43(12): 1431-7, 1996
   4		Mizowaki T., Nagata Y., Okajima K., Murata R., Yamamoto M., Kokubo M., Hiraoka M., Abe M.: Development of an MR simulator: experimental verification of geometric distortion and clinical application., Radiology, 199(3): 855-60, 1996
   5		Mizowaki T., Nishimura Y., Shimada Y., Nakano Y., Imamura M., Konishi J., M. Hiraoka: Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging., Int J Radiat Oncol Biol Phys, 36(5): 1091-8, 1996
   6		Murata R., Nishimura Y., Shibamoto Y., Hiraoka M., Abe M.: Changes in cell proliferative parameters of SCCVII and EMT6 murine tumors after single-dose irradiation., Jpn J Cancer Res, 87(6): 662-8 ,1996
   7		Murata R., Shibamoto Y., Miyauchi S., Hirohashi M., Takagi T., Sasai K., Oya N., Hiraoka M.: The combined antitumour effect of a new 5-fluorouracil derivative, BOF- A2, and radiation in vivo., Br J Cancer Suppl, 27: S114-6, 1996
   8		Nagata Y., Okajima K., Murata R., Mitsumori M., Mizowaki T., Yamamoto M., Hiraoka M., Nishidai T., Nakata M. , Abe M., Sugahara K., Arimura H., Hosoba M., Morisawa H., Kazusa C., Ai D., Kokubo M.: Development of an integrated radiotherapy network system., Int J Radiat Oncol Biol Phys, 34(5): 1105-11, 1996
   9		Nishimura Y., Murata R., Hiraoka M.: Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia., Br J Cancer, 73(3):270-4 , 1996
   10		Nishimura Y., Nagata Y., Okajima K., Mitsumori M., Hiraoka M., Masunaga S., Ono K., Shoji K., Kojima H.: Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control., Radiother Oncol, 40(3): 225-32, 1996
   11		Shibata T., Shibamoto Y., Sasai K., Oya N., Murata R., Takagi T., Hiraoka M., Abe M.: Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation., Jpn J Cancer Res, 87(1): 98-104 , 1996
   12		Ishikura S., Mitsumori M., Hiraoka M.: Clinical results of breast conserving therapy for stage I and II breast cancers: assessment of local recurrence in relation to surgical margins., Int. J. Clin. Oncol., 1: 170-75, 1996
   13		Shibata T., Shibamoto Y., Sasai K., Oya N., Murata R., Takagi T., Hiraoka M. , Takahashi M., Abe M.: Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay., Br J Cancer Suppl, 27: S61-4, 1996
   14		Harauchi H., Umeda T., Inamura K., Teshima T., Inoue T., Hishikawa Y., Ando Y., Fukuhisa K., Nagata Y., Okajima K., Murakami M.: Initial Data-element Selection and its Feasibility for the Development of a Multi-institutional Radiation Oncology Database., J. Jpn. Soc. Ther. Radiol. Oncol., 8: 335-45, 1996

   1995

   1		Hiraoka M., Mitsumori M., Okajima K., Okuno Y., Matsui K., Nakata M., Nagata Y., Takahashi M., Abe M.: Clinical results of breast-conservation therapy using a CT simulator., Gan To Kagaku Ryoho, 22(Suppl 3): 237-43, 1995
   2		Hiraoka M., Nishimura Y., Masunaga S., Koishi M., Mitsumori M., Y.P. Li, Nagata Y., Akuta K., Takahashi M., Abe M.: Clinical evaluation of 430 MHz microwave hyperthermia system with lens applicator for cancer therapy., Med Biol Eng Comput, 33(1): 44-7, 1995
   3		Hiraoka M., Nishimura Y., Nagata Y., Mitsumori M., Okuno Y., P.Y. Li, Takahashi M., Masunaga S., Akuta K., Koishi M., et al.: Clinical results of thermoradiotherapy for soft tissue tumours., Int J Hyperthermia, 11(3): 365-77, 1995
   4		Murata R., Nishimura Y., Hiraoka M., Abe M., Satoh M.: Manganese chloride treatment does not protect against acute radiation injury of skin or crypt cells., Radiat Res, 143(3): 316-9, 1995
   5		Nagata, Y., Hiraoka M., Nishimura Y., Masunaga S., Akuta K., Y.P. Li, Koishi M., Mitsumori M., Okuno Y., Takahashi M., et al.: Clinical experiences in the thermoradiotherapy for advanced gastric cancer., Int J Hyperthermia, 11(4): 501-10, 1995
   6		Nishimura Y., Hiraoka M., Mitsumori M., Okuno Y., Y.P. Li, Masunaga S., Koishi M., Akuta K., Abe M.: Thermoradiotherapy of superficial and subsurface tumours: analysis of thermal parameters and tumour response., Int J Hyperthermia, 11(5): 603-13, 1995
   7		Nagata Y., Okajima K., Murata R., Mizowaki T., Yamamoto S., Mitsumori M., Nishimura Y., Hiraoka M., Nishidai T., Nakata M., Abe M., Shibamoto Y., Takahashi M.: Development of the CT simulator and evaluation of its clinical efficacy., J. Jpn. Soc. Ther. Radiol. Oncol., 7: 65-75, 1995
   8		Ohtsu S., Miyakoshi J., Tsukada T., Hiraoka M., Abe M., Takebe H.: Enhancement of beta-galactosidase gene expression in rat pheochromocytoma cells by exposure to extremely low frequency magnetic fields., Biochem Biophys Res Commun, 212(1): 104-9, 1995

   1994

   1		Masunaga S., Hiraoka M., Akuta K., et al.: Phase I/II trial of preoperative thermoradiotherapy in the treatment of urinary bladder cancer., Int. J. Hyperthermia, 10(1): 31-40, 1994
   2		Ikenaga M., Ohura , Hiraoka M. et al.: Hyperthermic treatment of canine tibia through RF inductive heating of an intramedullary nail:a new experimental approach to hyperthermia for metastatic bone tumours., Int. J. Hyperthermia, 10(4): 507-16, 1994
   3		Hiraoka M., Kodama H., Mitsumori M., et al.: Preliminary results of quadrantectomy and radiation therapy for breast cancer., Breast Cancer, 1(2): 117-22, 1994
   4		Hiraoka M., Mitsumori M., Okajima K., et al.: Use of a CT simulator in radiotherapy treatment planning for breast conserving therapy., Radioth. Oncol., 33(1): 48-55, 1994
   5		Hiraoka M., Nishimura Y., Nagata Y., et al.: Site-specific phase I,II trials of hyperthermia at Kyoto University., Int. J. Hyperthermia, 10(3): 403-10, 1994
   6		Nishimura Y., Ono K., Tsutsui K., Oya N., Okajima K., Hiraoka M., Abe M.: Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation., Int J Radiat Oncol Biol Phys., 30(5): 1099-105, 1994
   7		Nagata Y., Okajima K., Murata R., Mitsumori M., Mizowaki T., Tsutsui K., Ono K., Nishimura Y., Hiraoka M., Nishidai T., et al.: Three-dimensional treatment planning for maxillary cancer using a CT simulator., Int J Radiat Oncol Biol Phys., 30(4): 979-83, 1994
   8		Mitsumori M., Hiraoka M., Shibata T., Okuno Y., Masunaga S., Koishi M., Okajima K., Nagata Y., Nishimura Y., Abe M., et al.: Development of intra-arterial hyperthermia using a dextran-magnetite complex., Int J Hyperthermia, 10(6): 785-93, 1994
   9		Matsumoto M., Yoshimura N., Honda Y., Hiraoka M., Ohura K.: Ferromagnetic hyperthermia in rabbit eyes using a new glass-ceramic thermoseed., Graefes Arch Clin Exp Ophthalmol.,232(3): 176-81, 1994

   1993

   1		Kikuchi M., Amemiya S.,Hiraoka M., et al.: Guide to the use of hyperthermic equipment. 1. Capacitively-coupled heating., Int. J. Hyperthermia, 9(2): 187-203, 1993
   2		Nagata Y., Ishigaki T., Okajima K., Fujiwara K., Kinashi T., Mitumori M., Ooya N., Kitakabu Y., Hiraoka M., Abe M., et al.: Transcatheter arterial infusion therapy combined with radical hysterectomy in the treatment of advanced cervical cancer., Cardiovasc Intervent Radiol., 16(1): 14-8; discussion 18-20, 1993
   3		Kikuchi M., Amemiya Y., Egawa S., Onoyama Y., Kato H., Kanai H., Saito Y., Tsukiyama I., Hiraoka M., Mizushina S., et al.: Guide to the use of hyperthermia equipment. 2. Microwave heating. The Japanese Society of Hyperthermic Oncology., Int J Hyperthermia, 9(3): 341-60, 1993
   4		Kikuchi M., Amemiya Y., Egawa S., Onoyama Y., Kato H., Kanai H., Saito Y., Tsukiyama I., Hiraoka M., Mizushina S., et al.: Guide for the protection of occupationally-exposed personnel in hyperthermia treatment from the potential hazards to health., Int J Hyperthermia, 9(4): 613-24, 1993